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The present study is designed to elucidate the interactions between the microbiota and indomethacin, an
NSAID that inhibits cyclooxygenases (COX) -1 and 2. At a dose that caused small intestinal damage, orally
administered indomethacin was distributed in the circulation and in the intestinal tract, and suppressed the
production of both COX-1 and COX-2 derived prostaglandins in vivo. Deep sequencing analysis showed that
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increased indomethacin elimination, and decreased its half-life and volume of distribution. This involves the
de-glucuronidation mediated by the β-glucuronidase-expressing bacteria in the intestinal microbiota.
Therefore, the intestinal microbiota may be a potential source of inter-individual variability in the
pharmacokinetics and/or pharmacodynamics of indomethacin.
This study also found that the total fecal microbial load, as well as the relative abundances of Bacteroidetes and
Firmicutes oscillated during the light-dark cycle. This oscillation requires a functional host circadian clock,
since deletion of Bmal1, a gene encoding a core molecular clock component, abolished this rhythmicity. The
fecal microbiota composition was also altered by Bmal1-deletion. In addition, the relative abundances of
several β-glucuronidase-expressing bacteria oscillate diurnally, suggesting the involvement of intestinal
microbiota in the chronopharmacology of indomethacin.
The indomethacin-microbiota interactions described here provide candidate mechanisms for pathogenesis of
GI toxicity, individualized drug responses, as well as the circadian variation of drug kinetics and effects.
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ABSTRACT 
BIDIRECTIONAL INTERACTIONS BETWEEN INDOMETHACIN AND THE 
MURINE INTESTINAL MICROBIOTA 
Xue Liang 
Garret A. FitzGerald, M.D. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their analgesic, 
antipyretic, and anti-inflammatory effects. However, NSAIDs commonly induce 
gastrointestinal toxicity by mechanisms that are incompletely understood, and the 
efficacy and side effects of these drugs exhibit significant inter-individual variability, 
which is partially explained by pharmacogenetics.  
The vertebrate intestinal microbiota have a highly diverse enzymatic system and hence 
have been implicated in the metabolism of various xenobiotics, including clinically 
important drugs. The composition of intestinal microbiota exhibits considerable inter-
individual differences, and dysbiosis has been associated with the pathogenesis of many 
diseases.  
The present study is designed to elucidate the interactions between the microbiota and 
indomethacin, an NSAID that inhibits cyclooxygenases (COX) -1 and 2. At a dose that 
caused small intestinal damage, orally administered indomethacin was distributed in the 
circulation and in the intestinal tract, and suppressed the production of both COX-1 and 
COX-2 derived prostaglandins in vivo. Deep sequencing analysis showed that 
indomethacin altered the composition and diversity of the large intestinal and fecal 
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microbiota, shifting it towards a pro-inflammatory phenotype. Depletion of the intestinal 
microbiota by antibiotic treatment increased indomethacin elimination, and decreased its 
half-life and volume of distribution. This involves the de-glucuronidation mediated by the 
β-glucuronidase-expressing bacteria in the intestinal microbiota. Therefore, the intestinal 
microbiota may be a potential source of inter-individual variability in the 
pharmacokinetics and/or pharmacodynamics of indomethacin.  
This study also found that the total fecal microbial load, as well as the relative 
abundances of Bacteroidetes and Firmicutes oscillated during the light-dark cycle. This 
oscillation requires a functional host circadian clock, since deletion of Bmal1, a gene 
encoding a core molecular clock component, abolished this rhythmicity. The fecal 
microbiota composition was also altered by Bmal1-deletion. In addition, the relative 
abundances of several β-glucuronidase-expressing bacteria oscillate diurnally, suggesting 
the involvement of intestinal microbiota in the chronopharmacology of indomethacin.  
The indomethacin-microbiota interactions described here provide candidate mechanisms 
for pathogenesis of GI toxicity, individualized drug responses, as well as the circadian 
variation of drug kinetics and effects.  
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Chapter 1 General Introduction 
1.1 Human gut microbiome 
The human body is home to a large collection of microbes, including bacteria, archaea, 
viruses, and unicellular eukaryotes, collectively referred to as the microbiome. Among 
them, bacteria are more intensely studied and hence better understood. It has been 
estimated that the human intestinal tract harbors over 100 trillion (10
14
) bacteria grouped 
in about 1000 species (Bengmark 1998, Ley, Peterson & Gordon 2006, Zhu et al. 2011), 
accounting for up to 98% of the intestinal microbiome (Manichanh et al. 2012). This 
collection of microbes is estimated to have a combined genome size exceeding that of 
humans by at least two orders of magnitude (Ley, Peterson & Gordon 2006).  
Although virtually all surfaces of the human body are colonized by bacteria, the most 
heavily colonized organ is the gastrointestinal tract, and the density in the colon reaches 
10
11
 to 10
12
 per milliliter (Whitman, Coleman & Wiebe 1998). The intestinal bacteria 
contribute greatly to host physiology, including the maintenance of mucosal structure 
(Stappenbeck, Hooper & Gordon 2002), host defense against pathogens (Bengmark 
1998), the activation of host immune responses (Littman, Pamer 2011), fermentation of 
dietary fiber (Sekirov et al. 2010), vitamin production for the host (such as biotin and 
vitamin K) (Stevens, Hume 1998), metabolism of peptides and proteins (Farthing 2004), 
and metabolism of xenobiotics, including drugs (Illing 1981, Bakke, Gustafsson 1986, 
Rowland et al. 1986). 
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The intestinal microbiota are dominated by Bacteroidetes and Firmicutes, which are just 
two of the 70 known phyla of Bacteria. Other minor constituents, including 
Actinobacteria, Proteobacteria and Verrucomicrobia, account for about 10% of the 
intestinal microbiota (Turnbaugh et al. 2007). However, the relative proportions of these 
phyla are different among different individuals (Eckburg et al. 2005, Arumugam et al. 
2011a). Furthermore, inter-individuality is also evident at lower taxonomic levels—the 
species presented in the intestine vary across individuals. Recently, attempts have been 
made to determine whether human beings share a core microbiota at species level. 
Several species are found to be present across individuals, such as Faecalibacterium 
prausnitzii, Roseburia intestinalis and Bacteroides uniformis (Qin et al. 2010). Yet in 
some individuals these phyla only account for less than 0.5% of the total microbes 
presented in the intestine (Turnbaugh et al. 2009). Variation even exists between 
genetically identical twins (Turnbaugh et al. 2010). Individuality of the gut microbiota 
composition was found to be shaped by multiple environmental and host genetic factors 
(Benson et al. 2010a). Hence, with about 6.7 billion human beings living on the Earth 
under various geographic, nutritional, and other conditions, the idea of a core microbiota 
among individuals is unlikely.  
Variability in the intestinal microbiota composition across individuals is driven by a 
variety of factors, including host genetics (Benson et al. 2010b), ageing (Biagi et al. 2010, 
Agans et al. 2011), lifestyle (Annalisa et al. 2014), pet ownership (Song et al. 2013), diet 
(Wu et al. 2011, Zoetendal, de Vos 2014), and time of day (Thaiss et al. 2014, Zarrinpar 
et al. 2014). For example, the intestinal microbiota composition of children living in 
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Europe is different from that of children living in a rural African village in Burkina Faso 
(De Filippo et al. 2010). Moreover, the intestinal microbiota composition of both children 
and adults from the United States is very different from that of children and adults from 
Malawi and the Amazonas states of Venezuela (Yatsunenko et al. 2012).  
The idea of enterotypes was developed, where the population was characterized by the 
dominance of Bacteroides, Prevotella or Ruminococcus, respectively, according to their 
relative proportions (Arumugam et al. 2011b). This concept is still under debate, since 
several later studies failed to reproduce the same clustering in detail (Wu et al. 2011, 
Yatsunenko et al. 2012). However, variability in the human intestinal microbiota 
composition is still evident. For instance, although not having identified all three 
enterotypes, a study of 98 healthy adults from the United States documented clustering of 
fecal communities at the levels of Bacteroides and Prevotella (Wu et al. 2011), 
recapitulating two of the original three enterotypes.  
The composition of intestinal microbiota is also affected by the physiological and disease 
state of host, and disruptions in the microbiota have been associated with obesity (Ley et 
al. 2006a, Turnbaugh et al. 2008, Zhao 2013), malnutrition (Kau et al. 2011), Crohn’s 
disease (Dicksved et al. 2008), inflammatory bowel disease (Frank et al. 2007), 
neurological disorders (Gonzalez et al. 2011), and cancer (Lampe 2008, Zhu et al. 2011, 
Chen et al. 2012, Zhu et al. 2014, Akin, Tozun 2014). Differences in the diversity, 
composition and function of the intestinal microbiota have been documented in these 
disease states when compared to healthy subjects. Furthermore, the use of antibiotics also 
affects the intestinal microbiota. For example, in healthy volunteers antibiotic treatment 
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led to major shifts in the dominant bacterial taxa within 24 hours of treatment, and in 
some subjects the changes persisted over a long time—from 2 months to 2 years (De La 
Cochetiere et al. 2005, Jernberg et al. 2007).  
1.2 Microbial metabolism of drugs 
Xenobiotics undergo the enzymatic conversion from lipophilic compounds that are 
readily absorbed into hydrophilic products that are excreted. Although liver is the major 
site, these conversions occur in other tissues, such as the gastrointestinal tract. Enzymes 
involved in xenobiotic metabolism include cytochrome P450 (CYP450) enzymes, 
carbonyl reductases, carboxylesterases, oxidase, reductase, hydrolase, as well as many 
transferases. Since the intestinal microbiome is highly diverse in enzymatic activities, it 
can metabolize many compounds.  For example, more than 30 approved drugs have been 
identified as direct substrates for colonic bacteria to date, including digoxin, 
sulfinpyrazone, clonazepam, L-dopa, 5-aminosalicylic acid, azetirelin (Sousa et al. 2008). 
Bacterial-mediated metabolism of drugs can be substantial. Co-administration of the 
antiviral drug, sorivudine with the prodrug for 5-Fluorouracil (5-FU) was implicated in 
18 deaths (Okuda et al. 1998). This is attributable to the inhibition of hepatic 
dihydropyrimidine dehydrogenase, a key enzyme regulating the systemic 5-FU level, by 
a bacteria-derived metabolite from sorivudine.  
Three mechanisms through which the gut microbiome performs biotransformation of 
drugs have been suggested. First, some species directly metabolize drugs, for example, by 
hydrolysis, glutathione conjugation and deamination (Sousa et al. 2008).  For example, 
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the prodrug sulfasalazine, prescribed for ulcerative colitis, is catalyzed by azoreductase 
encoded by colonic bacteria, releasing the active anti-inflammatory component 5-
aminosalicylic acid (Peppercorn, Goldman 1972). Bacteria-mediated biotransformations 
can also inactivate drugs, as in the case of the cardiac glycoside digoxin. Eubacterium 
lentum, a common anaerobe of the human colonic microbiota, is capable of converting 
digoxin to reduced derivatives that are pharmacologically inactive (Saha et al. 1983, 
Haiser et al. 2013, Haiser et al. 2014). Second, the intestinal microbiota can produce 
biologically active metabolites that are capable of competing with drugs for host-encoded 
catabolic enzymes. For example, bacteria-derived p-cresol can compete with 
acetaminophen for cytosolic sulfotransferase (Clayton et al. 2009). Third, the gut 
microbiota may modulate host drug metabolizing enzymes, such as cytochrome P450s 
and phase II conjugating enzymes. A recent study found a significant difference in 
colonic levels of several phase II xenobiotic-metabolizing enzymes including glutathione 
transferases, epoxide hydrolases, and sulfotransferases (Meinl et al. 2009).  
1.3 NSAIDs and cyclooxygenases 
The nonsteroidal anti-inflammatory drugs, or NSAIDs, are widely used anti-
inflammatory, analgesic, and antipyretic drugs. In the United States, annual prescription 
of these NSAIDs approaches 111 million, at a cost of $ 4.8 billion. These drugs also 
account for up to 60% of the over-the-counter analgesic market (Laine 2001).  
NSAIDs act by inhibiting the cyclooxygenase (COX) enzymes, which are also called 
prostaglandin G/H synthases. They are bi-functional enzymes which successively 
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metabolize arachidonic acid (AA) to cyclic endoperoxide prostaglandins G (PGG) and H 
(PGH), as shown in Figure 1.1.  
 
Figure 1.1 Metabolic pathways of prostanoids. Arachidonic acid (AA) is metabolized 
by COX-1 and COX-2 enzymes to produce PGH2, which is metabolized by isomerases 
and synthases into PGD2, PGE2, PGF2α, PGI2, and TXA2. NSAIDs act by inhibiting COX 
enzymes to achieve their pharmacological effects.   
 
There are two isoforms of cyclooxygenases, COX-1 and COX-2 (Smith, Garavito & 
DeWitt 1996). These two isoforms share 61% amino acid identity, and their crystal 
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structures are remarkably similar (FitzGerald, Loll 2001). Both isoforms have 
cyclooxygenase activity which oxygenates and cyclizes unesterified AA to form PGG2, 
and hydroperoxidase activity which converts PGG2 to PGH2 (Smith, Langenbach 2001). 
COX-1 and COX-2 have comparable Michaelis constant (Km) values for AA, despite 
some evidence that COX-2 is activated at lower peroxide concentrations than COX-1 
(Chen, Pawelek & Kulmacz 1999). COX-1 is constitutively expressed in most cells, 
whereas COX-2 expression is induced by cytokines, shear stress, and growth factors 
(Smith, Langenbach 2001). Therefore, COX-1 is mainly contributing PGs to 
housekeeping functions, and COX-2 is mainly contributing those relevant to 
inflammation and cancer (Murata et al. 1997, Goulet et al. 2004).  
1.4 Prostanoids 
Prostanoids are eicosanoids (derived from the Greek word εικωσι for 20) -- lipid 
mediators and products of AA, which is an unsaturated fatty acid constituent of cell 
membranes (C20:4). They are produced in a wide range of tissues, and play essential 
roles in human health and disease, such as blood clotting, wound healing, immune 
responses, bone metabolism, nerve growth and development, and inflammation (Ulrich, 
Bigler & Potter 2006). Prostaglandins are not stored in cells, but are synthesized and 
released when cells are activated (Funk 2001).  
AA is the most abundant precursor of eicosanoids in humans; it is either derived from 
dietary linoleic acid or ingested directly as a dietary constituent. Upon cell stimulation, 
AA is released from phospholipids in cellular membranes, and metabolized rapidly to 
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oxygenated products by several enzyme systems, including cyclooxygenase (COX), 
lipoxygenase (LOX), and CYPs (Grosser, Yu & FitzGerald 2010).  
As shown in Figure 1.1, COX-1 and COX-2 catalyze the biotransformation of AA to 
PGG2 and PGH2. The latter is then metabolized through isomerases and synthases effect 
into terminal prostanoids, including PGD2, PGE2, PGF2α, PGI2, and TXA2. Following 
their synthesis, these prostanoids are released from cells through facilitated transport 
(Schuster 2002), such as via the prostaglandin transporter, to exert autocrine or paracrine 
actions on a family of membrane expressed G protein coupled prostaglandin receptors 
(Funk 2001).   
1.5 tNSAIDs and pdNDSAIDs 
Despite their wide use, NSAIDs commonly induce gastrointestinal (GI) adverse effects. It 
has been estimated that NSAID-induced GI adverse events lead to over 100,000 
hospitalizations, US $2 billion in healthcare costs, and 17,000 deaths in the US each year 
(Frech, Go 2009).  
The inhibition of COX-2 activity is primarily driving the antipyretic, analgesic, and anti-
inflammatory effects of NSAIDs. COX-1 expression, however, is dominant and 
constitutive in gastric epithelium and is considered to play an important role in the 
cytoprotection at this site. Based on this evidence and the assumption that its inhibition 
would not be critical to NSAID induced enteropathy, purpose designed (pd) NSAIDs, 
which are selective inhibitors of COX-2 were developed (FitzGerald, Patrono 2001), in 
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the hope of reducing the undesired GI adverse  effects of tNSAIDs, most of which inhibit 
both COX-1 and COX-2.  
Celecoxib and rofecoxib were the first selective COX-2 inhibitors that entered the market. 
In a randomized double-blinded trial (Simon et al. 1999), the efficacy and incidence of GI 
complications of celecoxib and naproxen were compared in patients with symptomatic 
rheumatoid arthritis. It showed that the incidence of endoscopically visualized GI ulcers - 
a surrogate end point for adverse GI clinical outcomes - in patients receiving celecoxib 
was significantly lower compared to those receiving naproxen. The Vioxx 
Gastrointestinal Outcomes Research (VIGOR) trial (Bombardier et al. 2000) was 
conducted to assess the comparative risk of GI complications from rofecoxib and 
naproxen. Serious GI complications (perforation, obstruction, and severe upper 
gastrointestinal bleeding) were 54% lower in rofecoxib group compared to naproxen 
group. A placebo control group was not included but GI events still occurred in the 
rofecoxib group. By contrast, the Celebrex Long-term Arthritis Safety Study (CLASS) 
trial failed to detect a significant difference in the GI complications between celecoxib 
and diclofenac or ibuprofen when the entire data set was analyzed (Silverstein et al. 2000, 
Juni, Rutjes & Dieppe 2002).  Later, the Therapeutic Arthritis Research and 
Gastrointestinal Event Trial (TARGET) documented a three to four-fold reduction in 
ulcer complications in patients treated with lumiracoxib, a COX-2 selective inhibitor, 
compared to ibuprofen or naproxen (Schnitzer et al. 2004).  Results from these last two 
randomized clinical trials indicate that the distinction in GI outcomes between a tNSAID 
and a pdNSAID would be likely relative rather than absolute, and that our understanding 
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of the biology of COX enzymes and the distinct roles of the isoform enzymes are 
incomplete, raising the importance of further mechanistic investigations.  
1.6 NSAID-associated gastrointestinal adverse effects 
The mechanism of NSAID-induced GI toxicity is not completely understood, but at least 
three possibilities have been suggested. First, COX-1 inhibition in gastric epithelial cells 
reduces the production of mucosal cytoprotective prostaglandins, especially PGI2 and 
PGE2. These prostanoids inhibit gastric acid secretion, enhance mucosal blood flow and 
promote the secretion of cytoprotective mucus in the intestine. Second, COX-2 inhibition 
reduces angiogenesis and increases leucocyte adhesion, leading to impaired healing and 
leucocyte activation and subsequent mucosal injury. Third, NSAIDs cause local irritation 
from direct contact of orally administered drugs with the mucosa. This allows the acid to 
diffuse backwards into the mucosa and induces damage at the site (Somasundaram et al. 
1995, Rodriguez-Tellez et al. 2001, Abdel-Tawab, Zettl & Schubert-Zsilavecz 2009).  
Involvement of intestinal microbiota in NSAID-induced gastrointestinal adverse effect 
has also been suggested. For example, germ-free rats are resistant to intestinal lesions 
induced by indomethacin, which is a dual COX inhibitor; this resistance is greatly 
reduced by associating the animal with a single strain of E. coli. (Robert, Asano 1977). 
Moreover, co-administration of kanamycin, an aminoglycoside antibiotic, alleviates 
indomethacin-induced intestinal lesions in rats in a dose-dependent fashion (Koga et al. 
1999a).  
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Other studies have also suggested the involvement of intestinal microbiota in the adverse 
effects of NSAIDs. Kinouchi and colleagues showed that metabolites of Lactobacillus 
acidophilus and Bifidobacterium adolescentis inhibit ileal ulcer formation by repressing 
changes in the intestinal microbiota and lipid peroxidation in rats treated with BFMeT (5-
bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl) thiophene) (Kinouchi et al. 1998). 
Indomethacin treatment also increased microvascular leakage, accompanied by iNOS 
expression and activity in tissues; pretreatment with antibiotics reduced indomethacin-
induced microvascular leakage and iNOS activity (Evans, Whittle 2003).  
1.7 Metabolism of NSAIDs 
NSAIDs are metabolized in the liver via two major pathways: i) oxidation by cytochrome 
P450 enzymes (CYPs); and ii) glucuronidation by uridine-5'-diphosphate (UDP)-
glucuronosyltransferases (UGTs) (Figure 1.2) (Ulrich, Bigler & Potter 2006).  
The major cytochrome P450 enzyme responsible for the oxidation of NSAIDs is 
CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (Tracy et al. 1996, 
Hamman, Thompson & Hall 1997, Nakajima et al. 1998, Miners et al. 1996), although 
other P450 enzymes, such as CYP2C8, have also been found to metabolize NSAIDs 
(Zhao, Leemann & Dayer 1992). 
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Figure 1.2 NSAID metabolism pathways. The major metabolic pathways include 
cytochrome P45 enzymes (P450) –mediated oxidation, and uridine-5'-diphosphate 
(UDP)-glucuronosyltransferases (UGTs) –mediated glururonidation. A minor metabolic 
pathway includes sulphotransferases-mediated sulphate conjugation. (Adopted from 
Ulrich CM et al. Nat.Rev.Cancer. 2006 Feb; 6(2):130-140).  
 
Hepatic glucuronidation of NSAIDs are mainly catalyzed by multiple UGT enzymes, 
including UGT1A1, UGT1A9, UGT2B4, and UGT2B7 (Kuehl et al. 2005). UGT1A8 and 
UGT1A10, which are expressed in intestinal mucosa, have been shown to be involved in 
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NSAID glucuronidation as well (Cheng, Radominska-Pandya & Tephly 1999, Basu et al. 
2004). Some NSAIDs are conjugated with sulfate by sulfotransferases (Falany, Strom & 
Swedmark 2005, Ulrich, Bigler & Potter 2006). 
1.8 Inter-individual variability in NSAID pharmacology 
It is often claimed that individuals benefit uniquely from a particular NSAID although 
this has not been studied systematically (Lee, Goldstein & Pieper 2002). Determining 
whether and why individuals differ in their responses to NSAIDs are critical steps in the 
development of personalized approaches  to improve efficacy and safety.  
One of the likely sources of inter-individual variation of NSAID efficacy is variability in 
their metabolism through P450 and UGTs enzymes. Both enzyme families are highly 
polymorphic (Lee, Goldstein & Pieper 2002, Burchell 2003, Fries et al. 2006). For 
instance, the CYP2C9 L359 variant enzyme showed significantly decreased catalytic 
activity compared with the wild type enzyme, leading to reduced clearance of NSAIDs 
(Takanashi et al. 2000, Kirchheiner et al. 2003). Similarly, genetic variation of UGT1A6 
also affected its glucuronidation activity compared to the wild type enzyme (Ciotti et al. 
1997).   
Despite its importance, CYP2C-associated variability can only partially explain the 
variability amongst individuals in prostanoid inhibition by NSAIDs (Shah 2005, 
Kirchheiner, Brockmoller 2005, Fries et al. 2006). Considerations should also be given to 
environmental factors such as nutritional status(Hathcock 1985), the gut microbiota 
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(Wilson, Nicholson 2009, Clayton et al. 2006), patient age (Roberts, Tumer 1988), 
disease and the co- or pre-administration of other drugs (Clayton et al. 2006). 
1.9 Circadian rhythm  
The rotation of the earth results in the oscillation of light during the 24-hour cycle. 
Organisms adapted to this cycle by developing circadian rhythms based on an 
endogenous and entrainable mechanism that times daily events such as feeding, 
temperature, sleep-wakefulness, hormone secretion, and metabolic homeostasis (Saini et 
al. 2011, Green, Takahashi & Bass 2008). Circadian rhythms are important since they 
influence drug absorption, distribution, metabolism and excretion, resulting in the 
circadian variation if pharmacokinetics and pharmacodynamics.  
In mammals, this rhythm is controlled by a master clock that resides in the 
suprachiasmatic nucleus of the hypothalamus. It responds to the changing light cycle and 
signals this information to peripheral clocks in most tissues (Yang et al. 2013). Circadian 
rhythms also exist in fungi and cyanobacteria (Hut, Beersma 2011). For example, a 
pacemaker in cyanobacteria transduces the oscillating daylight signal to regulate gene 
expression and to time cell division (Johnson 2004, Iwasaki et al. 1999).  
The mammalian core clock is regulated tightly by interlocking feedback and feed-
forward loops at transcriptional, translational, and post-translational levels (Bass, 
Takahashi 2010, Xu et al. 2013), as shown in Figure 1.3.  
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Figure 1.3 The mammalian molecular circadian clock. The BMAL1/CLOCK 
heterodimer binds to E-box in the promoter regions of Per and Cry genes to activate their 
transcription. Once sufficient amounts of PER and CRY have been produced, they 
dimerize and relocate to the nucleus to inhibit BMAL1/CLOCK activity, hence their own 
transcription. In addition to this core loop, an interlocking loop was formed by ROR 
activation and REV-ERB repression of RORE-mediated transcriptions. These feedback 
loops control the rhythmic expression of clock-controlled genes (CCG) and downstream 
physiological processes.  
 
The BMAL1 and CLOCK heterodimer binds to the E-box motifs in the promoter regions 
of Per and Cry genes, forming the positive limb of the clock. PER and CRY dimerize and 
relocate to the nucleus, where they repress the activity of BMAL1/CLOCK complex, 
hence inhibiting the transcription of downstream genes, including their own. This forms 
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the negative limb of the clock. The retinoic acid receptor (RAR)–related orphan receptor 
gene (Ror) and the nuclear receptor–encoding Rev-erbα gene forms additional positive 
and negative loops.  
The core molecular clock exhibits a high degree of redundancy, where compensatory 
components are up-regulated in response to suppression of one gene in the loop. For 
example, in the absence of CLOCK, the transcription factor NPAS2 forms a heterodimer 
with BMAL1 (Baggs et al. 2009). Coincident deletion of both Clock and Npas2 genes is 
required for suppression of circadian behavior (DeBruyne, Weaver & Reppert 2007). 
Besides, both Per and Cry genes have isoforms (Per1 and Per2, Cry1 and Cry2, 
respectively), and deletion of Per1 and Per2 or Cry1 and Cry2 is required to ablate the 
rhythmicity of locomotor activity in mice (Baggs et al. 2009). 
In addition to the master clock residing in the suprachiasmatic nucleus, peripheral clocks 
exist in most tissues (Mohawk, Green & Takahashi 2012). The peripheral clocks not only 
respond to diverse hormonal and neuronal cues from the master clock, but also have 
autonomous behaviors. More recently, the peripheral clock in adipocytes has been shown 
to influence central feeding behavior by modulating lipid signaling to the feeding centers 
of the brain (Paschos et al. 2012).  
Besides the clock networks described in Figure 1.3, a non-transcriptional rhythm also 
exists. For example, self-sustainable oscillation of KaiC phosphorylation has been 
established in a test tube by incubating KaiC with KaiA, KaiB, and adenosine 
triphosphate (Nakajima et al. 2005).Although this is a quite distinct clock, peroxiredoxins, 
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highly conserved antioxidant proteins, have been shown to undergo redox oscillations in 
anucleate human red blood cells (O'Neill, Reddy 2011) and in algae, such as 
Ostreococcus tauri , in both cases independently of transcription (O'Neill et al. 2011). 
Recently, the KaiA, KaiB, and KaiC oscillator has been successfully transplanted to the 
noncircadian bacterium Escherichia coli (Chen et al. 2015). 
The circadian clock network is fundamental to maintaining many physiological processes, 
especially metabolism and immune function. Disruption of this system is associated with 
various disease phenotypes in mice, such as obesity, diabetes, atherosclerosis, cancer, 
neurodegeneration, and aging (Yang et al. 2013).  
1.10 Chronopharmacology 
It has long been known that systemic drug exposure varies with time of administration of 
the same doses. For example, amikacin, an aminoglycoside antibiotic used to treat 
different types of bacterial infections, shows significantly higher steady state levels when 
treated in the early morning hours than in evening (Elting et al. 1990). These changes 
during different time-of-day may be attributable to circadian rhythms.  
The absorption of nitrates (Scheidel, Lemmer 1991), benzodiazepines (Nakano et al. 
1984, Muller et al. 1987), calcium channel blockers (Lemmer et al. 1991), and 
acetaminophen (Kamali, Fry & Bell 1987) is more rapid when administered in the 
morning rather than in the evening. The concentration of acetaminophen glucuronide in 
urine during the first 4 hours after drug administration in the morning was found to be 
twice that when it was administered in the evening (Shively, Vesell 1975). The excretion 
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processes of drugs vary during different time of day, such as sulfonamides (Dettli, Spring 
1967). This may be explained by the temporal variation of urinary pH values.  
The cytochrome P450 monooxygenase system is mainly responsible for oxidation of 
drugs. The expression of cytochrome P450 has been shown to exhibit circadian 
rhythmicity (Panda et al. 2002). Consistently, the protein levels of cytochrome P450 
enzymes also show circadian rhythmicity (Lavery et al. 1999). In addition, mRNA of 
enzymes that are involved in the cytochrome P450 catalysis system also oscillates, 
including Alas1, which encodes the rate-limiting enzyme in heme biosynthesis (Panda et 
al. 2002), as well as the P450 oxidoreductase gene, which provides the electrons required 
for cytochrome P450-mediated monooxygenase reactions (Gachon et al. 2006). 
The interaction between the drug and its target is also subject to circadian variation. For 
example, components of the renin-angiotensin system, which plays an important role in 
the homeostasis of blood pressure, exhibit significant diurnal variation, with higher 
plasma renin activity during the night (Brandenberger et al. 1994). Indeed, molecules 
targeting this system are more effective when administered in the rest phase, such as 
angiotensin-converting enzyme inhibitor and an angiotensin II AT1-receptor antagonist 
(Schnecko, Witte & Lemmer 1995). Recently, a study revealed that almost 175 drugs 
target oscillating genes (Zhang et al. 2014c). Strikingly, this includes 56 of the top 100 
best-selling drugs in the United States (Zhang et al. 2014c).  
It is then expected that circadian timing of drug administration plays an important role in 
the effectiveness and safety of drugs. For example, the tolerance of 5-fluorouracil (5-FU), 
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an anti-cancer chemotherapy drug, has been shown to vary when delivered at different 
times of day (Bressolle et al. 1999), possibly due to the diurnal variation in the activities 
of enzymes involved in 5-FU metabolism and pharmacology, such as thymidylate 
synthase and dihydropyrimidine dehydrogenase (Harris et al. 1990). Indeed, clinical trials 
with a chronomodulated drug delivery paradigm showed increased responses and 
tolerability of 5-FU, leucovorin, and oxaliplatin compared to fixed-infusion-rate delivery 
(Levi et al. 1994, Levi, Zidani & Misset 1997).  
Chronomodulation of drug delivery may also expand the therapeutic index of drugs. For 
example, since 5-FU tolerability was significantly increased as a result of chronotherapy, 
an increase in dosing of 5-FU and in the frequency of administration in patients with 
metastatic colorectal cancer is allowed. As shown by another two trials, improved 
objective response rates and survival rates were achieved with this approach (Bertheault-
Cvitkovic et al. 1996, Levi et al. 1999).  
Despite the accumulated evidence suggesting benefits of chronomodulation in drug 
administration, clinical practice outside of cancer chemotherapy has been little influenced 
by the accumulation of such information (Abolmaali et al. 2009, Paschos et al. 2010).  
1.11 Scope of thesis research 
Despite a growing appreciation of the importance of the gut microbiome, few studies 
have addressed its importance in NSAID pharmacology and its potential relevance to 
their GI adverse effects. The main objective of my thesis research is to explore the 
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possibility of a bidirectional interaction between the intestinal microbiota and 
indomethacin using a mouse model.  
Indomethacin, a tNSAID that inhibits both COX-1 and COX-2 enzymes at therapeutic 
doses (Gierse et al. 1996), has been used to reduce fever, pain, stiffness, and swelling. It 
evokes gastrointestinal lesions in both humans as well as in experimental animal models 
(Brodie et al. 1970, Robert, Asano 1977, Stewart et al. 1980, Koga et al. 1999a). We 
selected indomethacin as a model drug with which to probe this interaction for the 
following reasons. i) The pharmacology of indomethacin as a mixed inhibitor of COX-1 
and COX-2 enzymes is well characterized in model systems and in humans. If an effect 
was detected, then we could proceed to selective inhibitors of COX-1 and COX-2 to 
characterize this interaction further. ii) Coincident inhibition/deletion of COX-1 and 
COX-2 is necessary to evoke GI lesions in mice and both tNSAIDs and pdNSAIDs cause 
GI lesions in humans. iii) Initial evidence exists showing that indomethacin induced 
compositional changes in the intestinal microbiota. iv) Indomethacin metabolism 
undergoes glucuronidation and involves enterohepatic recirculation, where the intestinal 
microbiota has been shown to play a role.  
The first aim of my thesis is to evaluate the composition of the luminal and tissue-
associated microbiota along the intestine in mice at baseline as background knowledge. 
The biomass, diversity, and composition of microbial communities were analyzed for 
both luminal contents and the mucosal tissues at the proximal, middle, and distal small 
intestine, the tip of cecum, as well as the proximal, middle, and distal large intestine.  
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The second aim is to investigate the influence of oral indomethacin administration on the 
intestinal microbiota composition along the intestinal tract. The biomass, diversity, and 
composition of microbial communities were compared cross-sectionally between 
indomethacin-treated mice and vehicle-treated mice in luminal contents and the mucosal 
tissues at the proximal, middle, and distal small intestine, the tip of cecum, as well as the 
proximal, middle, and distal large intestine. The biomass, diversity, and composition of 
microbial communities in feces were compared in indomethacin-treated mice before and 
after administration.  
The third aim is to determine whether the intestinal microbiota is involved in the 
metabolism of indomethacin. The pharmacokinetics of indomethacin was studied in mice 
treated with or without antibiotic cocktail. Glucuronidation of indomethacin was 
evaluated by collecting urine and feces samples from mice after indomethacin 
administration following the treatment with or without antibiotic cocktail. 
The fourth aim is to explore whether the intestinal microbiota composition in mice 
oscillates diurnally, by collecting feces from mice every 4 hours for 48 hours. Initial 
assessment of the influence of functional host circadian rhythm on the microbial 
oscillation during the light-dark cycle was conducted in mice lacking Bmal1, which is 
one of the major components of the mammalian circadian system. Gender differences 
were also evaluated in both wild type and Bmal1 knockout mice.  
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Chapter 2 Basal microbiota composition in murine intestine 
2.1 Introduction 
To evaluate the effect of indomethacin on the composition of the intestinal microbiota, it 
is important to analyze the composition of the luminal and tissue-associated microbiota 
along the intestine in untreated healthy mice.  
The microenvironments of the small intestine, cecum, and large intestine are subject to 
substantial differences in peristalsis, oxygen, enzymes, bile acids, urea, and others 
(Savage 1977, Walden, Hentges 1975, Mallory et al. 1973, Hoskins, Boulding 1976, 
Moreau, Ducluzeau & Raibaud 1976).  For a given GI site, luminal content and mucosal 
tissue also provide differential habitats for bacterial communities given the differences in 
mucus, oxygen, fluid flow rate, epithelial cells, immune barrier, and other factors (Savage 
1977, Albenberg et al. 2014). Yet to our knowledge, there is no comprehensive deep 
sequencing analysis characterizing the murine intestinal microbiota composition along 
the GI tract, although analysis has been done in dogs, cattle, and horses (Suchodolski et al. 
2005, Frey et al. 2010, Schoster et al. 2013), and studies have investigated modest 
numbers of different sites in mice (Hoffmann et al. 2009). Therefore, we conducted deep 
sequencing analysis on the intestinal microbiota composition in mice.  
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2.2 Materials and Methods 
2.2.1 Animals 
All C57BL/6 mice were purchased from the Jackson Laboratory and housed in our 
animal facility for at least 2 weeks before experiments. Male mice 10-14 weeks of age 
were used for all experiments. All animals were fed at libitum with regular chow diet 
(5010, LabDiet) for the course of study. Mice were kept under 12-hour light/12-hour dark 
(LD) cycle, with lights on at 7am and off at 7pm. Experimental protocols were reviewed 
and approved by the Institute for Animal Care and Use Committee at the University of 
Pennsylvania. 
2.2.2 Sample collection 
Twenty C57BL/6 mice were sacrificed and the whole intestine was isolated. Luminal 
contents and adjacent mucosal tissues at the proximal, middle, and distal regions of the 
small intestine, at the tip of cecum, as well as at the proximal, middle, and distal regions 
of the large intestine were isolated. The luminal contents were taken from the intestine 
(about 0.5 centimeter long) gently to avoid contamination by the mucosa. The adjacent 
mucosal tissues (about 0.5 centimeter long) were opened and washed in water until 
nothing visible came off the tissue. All samples were weighed and immediately stored at 
-80°C for following analysis. 
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2.2.3 DNA extraction for microbiota composition analysis 
DNA was extracted from samples with PSP Spin Stool DNA Plus Kit (Stratec) following 
the manufacturer’s instructions with slight modification. Previously collected samples 
were thawed on ice, and transferred to Lysing Matrix E tubes (MP Biomedicals) with 
1,400 μl of stool stabilizer from the PSP kit. They were then disrupted using the 
TissueLyser II (Qiagen) for 6 minutes at 30 Hz. Samples were then heated at 95°C for 15 
minutes, cooled on ice for 1 minute, and centrifuged at 13,400 g for 1 minute to pellet the 
debris. The supernatant was then transferred to the PSP InviAdsorb tubes, added with 400 
μl of stool stabilizer, vortexed for 15 seconds, incubated at room temperature for 1 
minute, and centrifuged at 16,000 g for 3 minutes. The supernatant was transferred to a 
new 1.5 mL receiver tube and centrifuged at 16,000 g for 3 minutes. 1 ml of the 
supernatant was transferred to a 2 mL safe-lock eppendorf tube containing 31.25 μl of 
Prot K and was incubated at 70°C for 10 minutes. 500 μl of Binding Buffer P was added 
and mixed by pipetting up and down. Then 700 μl of the mixture was transferred to RTA 
spin filter, incubated at room temperature for 1 minute, and centrifuged at 9,300 g for 2 
minutes. The filtrate was discarded and the spin filter was loaded with the rest of the 
mixture. Incubation and centrifuge was repeated, and the RTF filter was transferred to a 
new 2mL RTA Receiver Tube. Then the filter was loaded with 500 μl of Wash Buffer I, 
spun down at 9,300 g for 1 minute, and transferred to a new 2 mL RTA Receiver Tube. 
The filter was then loaded with 700 μl of Wash Buffer II and spun down at 9,300 g for 1 
minute. The filtrate was discarded. The filter was then returned to the receiver tube, spun 
at 16,000 g for 3 minutes to remove EtOH traces, and transferred to a new 1.5 mL 
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Receiver Tube pre-labeled with sample names. The following elution was conducted with 
adding 40 μl preheated (70°C) Elution Buffer D, incubation at room temperature for 1 
minute, and centrifuge at 9,300 g for 1 minute. A second elution was repeated with 30 μl 
preheated (70°C) Elution Buffer D to maximize the extraction efficiency. Extracted DNA 
was quantified using NanoDrop 1000 (Thermo Scientific) and stored at -20°C for future 
use.  
Every DNA extraction included a negative extraction control in which water was used 
instead of fecal pellets. All controls went through the same DNA extraction process as 
well as following amplification and sequencing processes.  
2.2.4 16S rRNA quantification 
Quantification of 16S rDNA was performed by real-time PCR using Taqman in triplicate 
reactions with 10 ng of DNA per reaction. Degenerate bacterial 16S rDNA-specific 
primers were used for amplification and their sequences were as follows: forward primer, 
5’-AGAGTTTGATCCTGGCTCAG-3; reverse primer, 5’-CTGCTGCCTYCCGTA-3’; 
probe: 5' - /56-FAM/TAA +CA+C ATG +CA+A GT+C GA/3BHQ_1/ - 3', + precedes 
the position of LNA base.  
Quantitative PCR was done on a 7900HT Real-Time PCR System (Applied Biosystems). 
Thermocycling was performed as follows: initiation at 95°C for 5 minutes followed by 40 
cycles of 94°C × 30 seconds, 50°C × 30 seconds, and 72°C × 30 seconds. Signals were 
collected during the elongation step at 72°C.  
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A standard curve prepared from a near full length clone of Escherichi coli 16S inserted 
into a Topo Vector was used for normalization for each run of real-time PCR.   
2.2.5 V1-V2 16S rRNA region amplification and sequencing 
100 ng of DNA was amplified with barcoded primers annealing to the V1-V2 region of 
the 16S rRNA using AccuPrime Taq DNA Polymerase System with Buffer 2 (Life 
Technologies). PCR reactions were performed on a thermocycler using the following 
conditions: initiation at 95°C for 5 minutes followed by 20 cycles of 95°C × 30 seconds, 
56°C × 30 seconds, and 72°C × 1 minute 30 seconds, then a final extension step at 72°C 
for 8 minutes. Each sample was amplified in quadruplicate. 
Amplicon purification was conducted with Agencourt AMPure XP beads (Beckman 
Coulter). 22 μl of each quadruplicate for each sample were pooled into a single eppendorf 
tube, resulting 88 μl of each sample. Each tube was added with 88 μl of AMPure Beads, 
votexted for 30 seconds, quickly centrifuged to remove the liquid from cap of tube, and 
placed in magnetic plate. After a 5-minute incubation at room temperature, the material 
was gently washed with 200 μl 70% ethanol over beads, and remove the supernatant. 
There was then a repeat ethanol wash, and incubation at 37°C for 10 minutes with the 
tubes open. Then the tubes were removed from the magnetic plate, and 50 μl of water 
was added. Then tubes were vortexed, quickly centrifuged, and placed back on the 
magnetic holder for 10-minute incubation. The water was pipetted into new pre-labeled 
eppendorf tube and stored at -20°C.  
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Purified amplicon DNA samples were then sequenced using the 454/Roche GS FLX 
Titanium chemistry (454 Life Sciences). 
2.2.6 16S rRNA sequencing analysis and bioinformatics 
Sequence data were processed with QIIME v 1.8.0 (Caporaso et al. 2010b) using default 
parameters, as shown in Figure 2.1.  
 
Figure 2.1 QIIME analysis pipeline. 
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Firstly, samples with less than 200 counts were removed from further analysis. Sequences 
were clustered into operational taxonomic units (OTUs) at 97% similarity and then 
assigned taxonomy using the uclust consensus taxonomy classifier. Sequences were 
aligned using PyNAST (Caporaso et al. 2010a) and a phylogenetic tree was constructed 
using FastTree (Price, Dehal & Arkin 2009). 
Weighted and unweighted UniFrac (Lozupone, Knight 2005) distances were calculated 
for each pair of samples for assessment of community similarity and generation of 
principal coordinate analysis (PCoA) plots. Taxonomic composition and alpha diversity 
were generated for each sample. To compare bacterial abundances across sample groups, 
group_significance.py was used with default parameters. 
2.2.7 PICRUSt analysis 
To estimate the functional profile for each microbiota sample, the reads were analyzed 
with Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt) version 1.0.0 (Langille et al. 2013). Closed reference OTUs were picked with 
QIIME from fasta files containing sequences of all samples, and corrected for multiple 
16S copy number using “Normalize by Copy Number” in PICRUSt analysis. The 
normalized OUT table was then used to generate a metagenome of KEGG (Kyoto 
Encylopedia of Genes and Genomes) ortholog abundances for each sample (Ogata et al. 
1999). Predicted metagenomes were collapsed into pathways, and analyzed with STAMP 
(Parks, Beiko 2010). 
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2.3 Results 
2.3.1 Geographic heterogeneity in the composition of the murine intestinal 
microbiota  
The intestinal microbiota composition is heterogeneous along the intestine as well as 
between luminal content and mucosal-associated tissue, as shown in Figure 2.2. The 
luminal content communities (square) form distinct clusters from mucosal tissue 
communities (triangle) using both unweighted UniFrac distances (describing the bacterial 
lineages presented in samples) and weighted UniFrac distances (describing the 
proportions of presented bacterial lineages in samples). This separation is more profound 
for mucosal-associated tissue.  
For both luminal contents and mucosal-associated tissues, microbiota composition in the 
small intestine has greater inter-mouse variation than that in the cecum or large intestine. 
As shown in Figure 2.2, small intestinal samples formed disperse clusters, indicating that 
there is greater inter-sample variability. By contrast, large intestinal samples are tightly 
clustered together. This is reflected in the heat maps showing the composition at GI sites 
as well in Figure 2.3. 
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Figure 2.2 Geographic heterogeneity of basal intestinal microbiota composition 
along the intestine in mice. Principal coordinate analysis (PCoA) of (A) unweighted 
UniFrac and (B) weighted UniFrac distances, depicting the comparison of microbial 
communities from luminal content (round), mucosal tissue (triangle), or feces (square). 
The base line microbiota compositions along the intestine are heterogeneous at 
anatomical sites. Each point represents a sample, and each sample is colored according to 
the habitat sites in the intestine. N=17-20. 
 
The fecal microbiota composition and large intestine luminal microbiota composition 
share great similarity. In the PCoA plots (Figure 2.2), clusters of fecal samples and those 
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of large intestine content samples are overlapping with each other, indicating a high 
similarity amongst such samples, both structurally and proportionally.  
2.3.2 Microbiota composition in the luminal content varies along the intestine 
 
Figure 2.3 Heat map of the microbiota composition in (A) luminal content and (B) 
mucosal tissue along the intestine. Each column represents one sample, and each row 
represents one phylum. The proportions of phyla are indicated by the color code to the 
right. Anatomical sites of the intestine are indicated at the bottom. N=17-20. 
 
In the luminal contents along the intestinal tract, Bacteroidetes and Firmicutes are the 
dominant phyla throughout the intestine (Figure 2.3 A). Firmicutes is more abundant in 
the cecum, whereas Bacteroidetes is the dominant population in the large intestine. In the 
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small intestine, however, the dominance of Bacteroidetes and Firmicutes vary among 
individuals.  
2.3.3 Microbiota composition in the mucosa-associated tissue varies along the 
intestine 
In the mucosa-associated tissues along the intestinal tract, Bacteroidetes and Firmicutes 
are the dominant phyla throughout the intestine, although other phyla, such as 
Proteobacteria, Actinobacteria, and Tenericutes, are also present in some regions (Figure 
2.3 B). Fimircutes are most abundant in the large intestine proximal region, and are also 
very abundant in the cecum and in the distal large intestine.  
In the small intestine, bacterial lineages of Firmicutes and Proteobacteria are presented, 
yet higher inter-individual variability in microbiota composition was evident.  
2.3.4 The predicted functions of luminal and mucosal microbiotas are different 
In addition to the microbiota composition, we also analyzed the predicted gene 
representations at different anatomical sites, using PICRUSt (Phylogenetic Investigation 
of Communities by Reconstruction of Unobserved States). This computational approach 
predicts the functional composition of microbiome using phylogeny data generated by 
16S rRNA sequencing and a public database of reference genomes (Langille et al. 2013). 
Predicted metagenome of KEGG ortholog abundances for each sample were generated 
and compared between the luminal content and mucosal tissue along the GI tract. The 
derived p-values are shown in the heat map (Figure 2.4).  
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Figure 2.4 p-value heat map of comparisons of predicted microbial functions 
between luminal content and mucosal tissue along the intestine. p-values of the 
differences between luminal content and mucosal tissue at each site were depicted in the 
heat map. Each column represents comparisons at one GI site. KEGG pathways are 
indicated to the right.  The p-values are indicated by the color to the right. The 
metagenomes in the large intestine are more divergent than the small intestine between 
luminal content and mucosal tissue. The small intestine middle and distal ends show 
some divergence. SI, small intestine; Ce, cecum; LI, large intestine. P, proximal; M, 
middle; D, distal. 
In addition to the compositional divergence in the luminal content and mucosal tissue 
microbiota, the gene representations in these communities are also different from each 
other, as shown in Figure 2.4.  
Although luminal and mucosal microbiota compositions in small intestine are more 
divergent (Figure 2.2), their predicted functions are not as different (Figure 2.4). By 
contrast, the predicted functions of luminal and mucosal microbiota in the large intestine 
are significantly different (Figure 2.4), despite much smaller dissimilarity in their 
composition (Figure 2.2). Not surprisingly, predicted functions of cecal microbiota in 
both luminal content and mucosal tissue share high similarity (Figure 2.4), given that 
they clustered closely in compositional analysis (Figure 2.2). 
The luminal microbiome in the large intestine is enriched in genes involved in (i) 
metabolism of amino acids, energy, glycan, cofactors, vitamins, terpenoids, polyketides, 
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and nucleotides, (ii) signaling molecules and their interaction, (iii) cell growth and death, 
(iv) genetic information processing pathways including translation, folding, sorting and 
degradation, replication and repair. The mucosal microbiome in the large intestine is 
enriched in genes involved in (i) environmental information processing pathways such as 
membrane transport and signal transduction, (ii) cell motility and environmental adaption, 
(iii) xenobiotic biodegradation and metabolism. 
2.4 Discussion 
We showed that the intestinal microbiota composition bears great heterogeneity at 
different sites along the intestine. At each of these sites luminal and mucosal microbiota 
composition also vary. Although compositionally less different, the large intestine 
microbiota function differentially in luminal content versus in mucosal tissue. 
Previous studies revealed compositional differences in microbiota along the GI tract in 
dogs, cattle, and horses (Suchodolski et al. 2005, Frey et al. 2010, Schoster et al. 2013). 
However, our study is the first one to use deep sequencing technology to show the 
distinction amongst microbiota at various regions of the GI tract in mice. Collectively, 
the microbiota composition along the intestine shows great geographic heterogeneity.  
The ever-improving sequencing technology has potentiated the blooming of intestinal 
microbiome studies over the past several years. The majority of the studies, especially 
those of the human microbiome, collect fecal samples to minimize the level of 
invasiveness (Kuczynski et al. 2011). However, the mucosa-associated microbiota in the 
colon are significantly different from those in feces (Zoetendal et al. 2002). Indeed, we 
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observed a similar pattern in mice by showing the significant separation between large 
intestine mucosal microbiota and fecal microbiota (Figure 2.2). Nevertheless, as shown in 
the PCoA plots, bacterial communities in feces share high similarity with the large 
intestine content. Hence, it is reasonable to use feces as indirectly representative of the 
colon lumen. However, for studies focusing on the lining of the GI tract, or focusing on 
different regions of the GI tract, there is little choice but to collect biopsy samples.  
Bacterial communities in the small intestine are highly variable among individuals 
(Figure 2.2). This is at least partially shaped by the dynamic local microenvironment 
(Savage 1977). For instance, the small intestine sees the food, water, and air constantly 
coming in, and it has high flow rates of the content. 
The genetic enrichment of the large intestine luminal microbiome in metabolism, cell 
growth and death, and signaling pathways reflects its dynamic interaction with contents 
containing nutrients and food debris, while the mucosal microbiome is associated with 
abundant environmental information processing pathways, reflective of its intimacy and 
communication with host epithelium. 
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Chapter 3 Indomethacin causes changes in the microbiota 
composition 
3.1 Introduction 
Coincidental disruption of both COX enzymes, such as is achieved by indomethacin at 
therapeutic doses in humans, is necessary to evoke gastrointestinal lesions in 
experimental animals (Wallace et al. 2000, Tanaka et al. 2001, Sigthorsson et al. 2002, 
Takeuchi et al. 2010). However, germ-free rats are resistant to indomethacin-induced 
intestinal lesions, and the resistance was dramatically reduced when these rats were 
associated with a single strain of E coli. (Robert, Asano 1977). Moreover, an independent 
study showed that pretreatment of rats with antibiotics attenuated indomethacin-induced 
enteropathy in a dose-dependent fashion (Koga et al. 1999b). These studies indicate that 
indomethacin-induced gastrointestinal toxicity is bacteria dependent.  
Limited information is available as to the impact of NSAIDs on the intestinal microbiota. 
5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl) thiophene (DuP 697), an 
experimental COX-2 inhibitor, increased the percentage of gram-negative rods from 1.5% 
to 49.8% in rats (Kinouchi et al. 1998). Indomethacin resulted in a 1000-fold increase of 
Enterococcus faecalis and a relative diminution of segmented filamentous bacteria (SFB) 
(Dalby et al. 2006). However, one limitation of these studies is that the technology is not 
sensitive or comprehensive. Besides, no studies have been done in mice, which is a 
helpful tool for mechanistic studies.  
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A more recent study in humans showed that the use of NSAIDs may interact with host 
age to influence the composition of intestinal microbiota (Makivuokko et al. 2010). It 
was found that the relative abundance of Roseburia, Ruminococcus, and Collinsella spp. 
were decreased in elderly NSAID users compared to young adults. Limitations of this 
study include a small sample size, the use of miscellaneous NSAIDs, uncharacterized for 
their COX selectivity, and a less than comprehensive microbiota analysis.  
Collectively, despite initial evidence on the effect of NSAIDs on the composition of the 
intestinal microbiota, a detailed, well-designed, and comprehensive study using deep 
sequencing is still needed to elucidate the effect of indomethacin treatment on the 
composition of intestinal microbiota in mice. 
3.2 Materials and Methods 
3.2.1 Animals 
All C57BL/6 mice were purchased from the Jackson Laboratory and housed in our 
animal facility for at least 2 weeks before the experiment. Male mice 10-14 weeks of age 
were used for all experiments. All animals were fed at libitum with a regular chow diet 
(5010, LabDiet) for the course of study. Mice were kept under a 12-hour light/12-hour 
dark (LD) cycle, with lights on at 7am and off at 7pm. Experimental protocols were 
reviewed and approved by the Institute for Animal Care and Use Committee at the 
University of Pennsylvania. 
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3.2.2 Study design 
At 12pm, non-fasted mice were administered by gavage with 10 mg/Kg indomethacin (in 
PEG400), or with PEG400, or left untreated. Each group included 20 male mice. To 
evaluate indomethacin-induced compositional changes in gut microbiota composition, 
fecal pellets were collected prior to and 6 hours post drug administration. Then mice were 
sacrificed to sample the luminal contents and adjacent mucosal tissues at the proximal, 
middle, and distal regions of the small intestine and large intestine, as well as at the tip of 
cecum. The study design is illustrated in Figure 3.1. All samples were weighed, placed in 
empty vials, and immediately stored at -80°C for microbiota composition analysis. 
 
Figure 3.1 The study design of indomethacin-induced compositional changes in 
murine microbiota. 
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In the experiment to evaluate indomethacin-induced intestinal damage, mice were 
sacrificed 24 hours after administration to harvest their small intestines for future 
histological analysis.  
In another experiment to evaluate the inhibitory effect of indomethacin, mice were 
housed individually in metabolic cages after indomethacin or PEG400 administration for 
6 hours to collect their urine and fecal pellets. Each group included 10 mice. Then mice 
were sacrificed to harvest their intestines. Urinary prostanoid metabolites were 
determined by mass spectrometric quantitation. Indomethacin concentrations were 
quantified in urine, feces, and in the luminal contents and mucosal tissues at the proximal, 
middle, and distal regions of small intestine and large intestine, as well as at the tip of 
cecum. 
3.2.3 Histological analysis of small intestinal damages 
Histology of the injured small intestine was analyzed as described (Imaoka et al. 2010). 
Briefly, small intestine were removed and perfused with phosphate buffered saline (PBS). 
Tissues were opened along the anti-mesenteric attachment and pinned down for 
macroscopic examination. The injured segments of the small intestine were trimmed, 
fixed overnight in 4% (vol/vol) paraformaldehyde at 4°C, washed with PBS, and 
dehydrated with ethanol before embedding in paraffin. Sections were cut and stained with 
hematoxylin and eosin (H&E) staining.  
The degree of inflammation was microscopically graded from 0 to 3 as follows. Grade 0: 
no signs of inflammation; Grade 1: increased mucosal neutrophils or lymphocytes present; 
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Grade 2: increased mucosal and submucosal or transmural neutrophils or lymphocytes 
present; Grade3, mucosal regenerative features with a shortening of villi or ulcers or 
erosions.  
3.2.4 Sample preparation for mass spectrometric analysis of prostanoids 
Mouse urine (~100 μl) was spiked with 50 μl mixed stable isotope labelled internal 
standards. Sample was derivatized with 75 µl methoxime (in HCl) for 15 min at room 
temperature before solid-phase extraction (SPE).  
3.2.5 Sample preparation for mass spectrometric analysis of indomethacin 
Tissue and fecal samples were homogenized in 1 ml Millipore H2O and briefly 
centrifuged. Samples were added with 2500 ng d4-indomethacin, vortexed, and incubated 
at room temperature for 15 min. Samples were centrifuged at 16000 g for 15 min and the 
upper layer was transferred to a new tube. 100 μl of the supernatant was added with 900 
μl H2O before solid phase extraction (SPE). 
Plasma samples (~10 μl) were mixed with 50 μl indomethacin internal standard (300 ng 
in ACN), 20 μl formic acid and 900 μl H2O. Samples were vortexed and centrifuged 
before solid phase extraction (SPE).  
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3.2.6 Solid-phase extraction  
Solid-phase extraction (SPE) was performed according to the Manufacturer's instructions 
(Strata-X, Phenomenex). Indomethacin and its metabolites were eluted with 1 ml 
methanol. Prostanoid metabolites were eluted with 1 ml 5% ACN (in ethyl acetate). 
3.2.7 Calibration curves for mass spectrometric analysis 
 To calculate the precise relative amount of indomethacin metabolites, standard curves 
were prepared in mouse urine. Individual stock solutions of each compound (100 ng/µl) 
were prepared in ACN and stored at -80°C. Working solutions were prepared by mixing 
equal amounts of corresponding stock solutions and performing serial dilutions with 
ACN. Seven point calibration samples (0, 0.032, 0.16, 0.8, 4, 20 and 100 ng/µl) for 
indomethacin were prepared. One large urine sample was obtained from mice without 
exposure to indomethacin. For each sample, 40 µl of (1 ng/µl) d4-Indomethacin (Santa 
Cruz Biotechnology), 10 µl calibration standards were added to 20 mouse urine. The 
samples were extracted by SPE before LC/MS. 
3.2.8 Liquid chromatography/mass spectrometry for indomethacin 
Indomethacin was measured using a TSQ Quantum Ultra™ triple quadrupole mass 
spectrometer (Thermo Scientific) equipped with an ESI ion source. The Mass 
Spectrometer was connected to a Thermo Scientific Accela HPLC Systems and equipped 
with a PAL auto sampler and thermocontroller (set at 4°C). The CSH C18 Column (2.1 
mm X 150 mm, 130Å, 1.7 µm, Waters) was used at a constant 40°C. The mobile phase 
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(A) (90% H2O/10% (B),  0.2% acetic acid) and mobile (B) (90% ACN/10% methanol) 
was used at a flow rate of 350 μl/min with a binary gradient (0-12 min, 10-50% B; 12-
12.5 min, 50-100% B; 12.5-16 min, 100% B; 16.2-20 min, 10% B). Mass spectrometry 
was performed in negative mode. The transition for Indomethacin and d4-Indomethacin 
are 355.9>311.9 and 359.9>315.9, respectively. Both Q1 and Q3 were operated at 0.7 
m/z FWHM. Peak area ratios of target analytes to d4-Indomethacin internal standards 
were calculated by Xcalibur Quan software. The data were fitted to the calibration curves 
to calculate the precise relative amount of indomethacin.  
3.2.9 Liquid chromatography/mass spectrometry for prostanoids 
Prostanoid metabolites were measured using a Waters Acquity UPLC system comprising 
a binary pump, an autosampler, and a Xevo TQ-S triple quadrupole mass spectrometer 
equipped with an electrospray ionization source (Waters Corporation). Chromatographic 
separation was performed on a Waters UPLC CSH C18 column (2.1 mm X 150 mm, 
130Å, 1.7 µm). The UPLC mobile phases consisted of (A) (95%H2O/5% (B), pH=5.7) 
and (B) 95%ACN/5% methanol. The initial gradient began with 0% B. Mobile phase B 
increased linearly to 10% at 17 min, to 10.5% at 17.5min, to 11.5% at 32 min, to 20% at 
35 min, to 43% at 43 min, to 100% at 43.5 min, and finally go back to 0% at 45.5 min . A 
0.35 ml/min flow rate was used throughout the UPLC gradient. The autosampler 
temperature was set at 4 °C and the UPLC column was heated at 50°C. The MS was 
operated under negative ion mode at MRM mode. The transitions were monitored as 
previously described (Song et al. 2007). Briefly, systemic production of PGI2, PGE2, 
PGD2, and TxB2 was determined by quantifying their major urinary metabolites: 2, 3-
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dinor 6-keto PGF1α (PGI-M); 7-hydroxy-5, 11-diketotetranorprostane-1, 16-dioic acid 
(PGE-M); 11, 15-dioxo-9α-hydroxy-2, 3, 4, 5-tetranorprostan-1, 20-dioic acid (tetranor 
PGD-M); and 2, 3-dinor TxB2 (Tx-M), respectively. Results were normalized with 
creatinine (Oxford Biomedical Research). Peak areas were obtained using MassLynx® 
software (Waters Corporation). 
3.2.10 DNA extraction for microbiota composition analysis 
DNA extraction was performed as described in Chapter 2 (2.2.3). 
3.2.11 16S rRNA quantification 
Quantification of 16S rRNA was performed by real-time PCR as described in Chapter 2 
(2.2.4). 
3.2.12 V1-V2 16S rRNA region amplification and sequencing 
16S rRNA gene amplification was performed as described in Chapter 2 (2.2.5). 
3.2.13  Bioinformatics 
Sequence data were processed with QIIME v 1.8.0 (Caporaso et al. 2010c) using default 
parameters, as described in Chapter 2 (2.2.6).  
3.3 Results 
3.3.1 Mice are systemically and locally exposed to indomethacin 
Exposure to indomethacin was measured by mass spectrometry.  
 45 
 
 
Figure 3.2 C57BL/6 mice are systemically and locally exposed to indomethacin. 
Indomethacin concentrations were measured in samples and corrected by sample weight. 
Indomethacin is detected along the intestine in both (A) luminal content and (B) mucosal 
tissue in mice of indomethacin (red) group, but not in those of PEG400 (blue) or 
untreated (black) groups. In (C) feces, (D) urine, and (E) plasma, indomethacin is also 
detected in mice of indomethacin (red) group, but not in those of PEG400 (blue) or 
untreated (black) groups. N=10/group. Mean ± S.E.M. shown. SI, small intestine; Ce, 
cecum; LI, large intestine. P, proximal; M, middle; D, distal.  
 
As shown in Figure 3.2, indomethacin was readily detected, both systemically and locally, 
in indomethacin-treated mice. The average indomethacin level in plasma was 35.5 μg/ml. 
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Indomethacin was also detected in urine and feces due to fecal and urinary excretion, 
with the average level of 1.58 μg/ml and 0.53 ng/mg, respectively. The intestine was fully 
exposed to indomethacin, forming a gradient from small intestine luminal content (5.1 
ng/mg tissue on average), through small intestine mucosa (0.53 ng/mg tissue on average), 
cecum luminal content (1.11 ng/mg tissue on average) and mucosa (0.77 ng/mg tissue on 
average) to large intestine luminal content (0.6 ng/mg tissue on average) and mucosa 
(0.44 ng/mg on average).  
3.3.2 Indomethacin inhibits both COX-1 and COX-2 in mice 
Eicosanoid biosynthesis was estimated by measuring their corresponding urinary 
metabolites using mass spectrometry, as shown in Figure 3.3. Compared to untreated and 
PEG400-treated mice, indomethacin treatment caused 74.6% reduction in the urinary 
PGD-M (the major PGD2 metabolite) concentration, 82.9% reduction in the urinary PGE-
M (the major PGE2 metabolite) concentration, 53.1% reduction in the urinary PGI-M (the 
major PGI2 metabolite) concentration, and 87.4% reduction in the urinary Tx-M (the 
major metabolite of TxA2) concentration, indicating the suppression of prostanoid 
production by indomethacin. Among these, PGD2 and TxA2 are primarily derived from 
COX-1, whereas PGE2 and PGI2 are primarily derived from COX-2. Therefore, both 
COX-1 and COX-2 were inhibited by 6-hour treatment of a single oral dose of 10 mg/kg 
indomethacin in mice. 
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Figure 3.3 Inhibitory effects of indomethacin on COX-1 and COX-2 in C57BL/6 
mice. Mice were administered by gavage with or without 10mg/Kg indomethacin (red) or 
PEG400 (blue) and urine were collected for the analysis of prostanoid metabolites. (A) 
PGD-M, (B) PGE-M, (C) PGI-M, and (D) Tx-M are reduced in indomethacin-treated 
mice. N=6/group. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 by Kruskal-
Wallis test, multiplicity adjusted. Mean ± S.E.M. shown. 
3.3.3 Indomethacin induces injury in the small intestine  
A single oral dose of 10 mg/kg indomethacin induced small intestinal damage in mice 
within 24 hours of drug administration. Indomethacin induced severe intestinal damage 
compared to vehicle (PEG400) treatment. Beside, indomethacin mostly caused Grade 3 
damage, which includes shortening of villi, ulcers or erosions (Figure 3.4 A). 
Representative H&E staining sections of Grade 3 injuries were shown in Figure 3.4 B.  
 48 
 
 
Figure 3.4 Indomethacin induces small intestinal damages in C57BL/6 mice. (A) 
Frequency of indomethacin induced small intestinal injuries that are categorized into 4 
grades. (B) Representative sections of hematoxylin and eosin staining of injured small 
intestine 24 hours after 10 mg/Kg indomethacin treatment.  
 
3.3.4 Bacterial load along the intestine is not altered by indomethacin 
Cross-sectional analysis of the luminal contents and mucosal tissues along the intestine 
showed that indomethacin barely caused changes in16S gene copy numbers, despite a 
slight decrease in middle large intestine luminal content and proximal large intestine 
mucosal-associated tissue (Figure 3.5). Therefore, 10 mg/Kg indomethacin treatment had 
no effect on the bacterial load along the intestine.  
A vehicle effect was evident (Figure 3.5). Mice treated with PEG400 showed a decrease 
in luminal biomasses and an increase in mucosal tissue biomasses in the distal end of 
large intestine, compared to untreated mice.  
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Figure 3.5 Bacterial biomasses at anatomical sites along the intestine. 16S rRNA 
gene copies per gram of (A) luminal contents and (B) mucosal tissues at anatomical sites 
along the intestine in indomethacin (red), PEG400 (blue), and untreated (black) groups. 
Microbial loads at anatomical sites along the intestine are barely different between 
PEG400 and indomethacin groups, although PEG400 causes changes by itself. ** p < 
0.01 by multiple t test comparing PEG400 versus indomethacin groups, FDR corrected. # 
p < 0.05, ### p < 0.001, #### p < 0.0001 by multiple t test comparing untreated versus 
PEG400 groups, FDR corrected. N=20/group. Mean ± S.E.M. shown. SI, small intestine; 
Ce, cecum; LI, large intestine. P, proximal; M, middle; D, distal.  
 
3.3.5 Alpha diversities are altered in colon 
Microbial communities along the intestine were analyzed by evaluating species richness 
and diversity measured by the Observed Species and Shannon Index. Comparison 
between the indomethacin and PEG400 groups revealed changes in the large intestine.  
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Figure 3.6 Bacterial diversity at anatomical sites along the intestine. (A) Observed 
Species of luminal content. (B) Observed Species of mucosal-associated tissue. (C) 
Shannon Index of luminal content. (D) Shannon Index of mucosal-associated tissue. 
Richness and diversity of microbial communities were shown for indomethacin (red), 
PEG400 (blue), and untreated (black) groups. Indomethacin altered microbial diversity in 
the distal intestine, although PEG400 also causes changes in the distal intestine by itself. 
* p < 0.05, ** p < 0.01, *** p < 0.001 by multiple t test comparing PEG400 versus 
indomethacin groups, FDR corrected. # p < 0.05, ### p < 0.001, #### p < 0.0001 by 
multiple t test comparing untreated versus PEG400 groups, FDR corrected. N=20/group. 
SI, small intestine; Ce, cecum; LI, large intestine. P, proximal; M, middle; D, distal. 
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Indomethacin caused an increase in Observed Species (Figure 3.6 A, B) in the middle and 
distal large intestine luminal content, as well as in feces, without affecting the mucosal 
tissues. The Shannon Index (Figure 3.6 C, D) was decreased in the luminal content of the 
cecum and in the mucosal tissue of proximal large intestine, and increased in feces. 
PEG400 alone increased microbial diversity in the distal large intestine. For example, 
PEG400 induced increase of observed species in the large intestine middle and distal 
mucosa tissues, increase of Shannon index in the large intestine middle and distal luminal 
content, as well as increase of Shannon index in the large intestine proximal and middle 
mucosa tissues. 
3.3.6 Indomethacin induces changes in luminal and mucosal microbiota composition 
Indomethacin induced compositional changes in intestinal microbiota primarily in the 
large intestine. Principal coordinate analysis (PCoA) revealed significant separation of 
bacterial communities between indomethacin- or PEG400-treated mice, as shown in 
Figure 3.7. Statistics of PCoA was presented in Table 3-1.  
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Figure 3.7 Indomethacin-induced compositional changes in the large intestine. 
Principal coordinate analysis (PCoA) of unweighted UniFrac (UW) and weighted 
UniFrac (W) distances, depicting the comparison of microbial communities from 
indomethacin (blue), PEG400 (red), and untreated (green) groups at anatomical sites in 
large intestine. Each point represents a sample, and each sample is colored according to 
the habitat sites in the intestine. N=17-20. LI, large intestine. P, proximal; M, middle; D, 
distal. 
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Table 3-1 PCoA statistics of indomethacin-induced microbial changes 
GI site Sample type 
UniFrac 
distance type 
q-value by 
PERMANOVA 
Pairwise 
comparison 
(PEG400 vs. 
Indomethacin) 
Proximal 
large intestine 
Mucosal tissue Unweighted 0.001 0.009 
Proximal 
large intestine 
Mucosal tissue Weighted 0.001 0.004 
Middle large 
intestine 
Mucosal tissue Unweighted 0.001 0.026 
Middle large 
intestine 
Mucosal tissue Weighted 0.001 0.009 
Distal large 
intestine 
Mucosal tissue Unweighted 0.001 0.006 
Distal large 
intestine 
Mucosal tissue Weighted 0.004 0.009 
Distal large 
intestine 
Luminal 
content 
Unweighted 0.002 0.036 
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Figure 3.8 Indomethacin-induced changes in bacterial abundances. The relative 
abundance of (A) Peptococcaceae in luminal content, (B) Peptococcaceae in mucosal 
tissue, (C) Erysipelotrichaceae in luminal content, and (D) Erysipelotrichaceae in 
mucosal tissue at anatomical sites along the intestine are significantly elevated in 
indomethacin (red) group than in PEG400 (blue) and untreated (black) groups.  * p < 
0.05, *** p < 0.001 by QIIME analysis, FDR corrected. Mean ± S.E.M. shown. SI, small 
intestine; Ce, cecum; LI, large intestine. P, proximal; M, middle; D, distal. 
 
The abundance of discrete bacterial lineages was also affected by indomethacin. 
Peptococcaceae expanded in the luminal content of cecum, the proximal and distal large 
intestine, as well as in mucosal tissues of the cecum and the proximal large intestine, as 
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shown in Figure 3.8 A and B. Erysipelotrichaceae expanded in the mucosal tissues of 
cecum and middle large intestine, yet were less affected in the luminal content, as shown 
in Figure 3.8 C and D.  
3.3.7 Indomethacin has no effect on fecal microbial biomass  
 
Figure 3.9 Indomethacin has no effect on fecal microbial biomass. (A) 16S rRNA 
gene copies per gram of feces at 0h and 6h in indomethacin (red), PEG400 (blue), and 
untreated (black) groups. (B) Fold changes of 6h-to-0h 16S rRNA gene copy number in 
indomethacin (red), PEG400 (blue), and untreated (black) groups. Both PEG400 and 
indomethacin groups have lower bacterial load at 6h, whereas these is no between-group 
differences at 0h or 6h.  **** p < 0.0001 by Mann-Whitney test  comparing 0h versus 6h. 
N=20/group. Mean ± S.E.M. shown. 
 
To address the longitudinal effect of indomethacin on fecal microbiota biomass, 16S 
rRNA gene copy numbers before and after indomethacin administration were evaluated. 
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As shown in Figure 3.9 A, both the PEG400 and indomethacin-treated groups showed a 
significant reduction in 16S rRNA gene copy numbers, indicating a reduced biomass over 
time. However, statistical analysis revealed no difference between PEG400 and 
indomethacin groups either before (0h) or after (6h) treatment (Figure 3.9 B), indicating 
that the reductions in both groups was due to a vehicle effect. Therefore, indomethacin 
had no effect on fecal microbial biomass. 
3.3.8 Indomethacin increases fecal microbial diversity 
The longitudinal effect of indomethacin on microbial evenness and diversity was 
evaluated by measuring Observed species and the Shannon index.  
 
Figure 3.10 Indomethacin increases fecal microbial diversity. (A) Observed Species 
and (B) Shannon Index are increased at 6h in indomethacin-treated mice, while 
unchanged in Untreated and PEG400 groups.  ** p < 0.01 by multiple t test, FDR 
corrected. N=19-20/group. Mean ± S.E.M. shown. 
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The Shannon index was significantly increased 6 hours after indomethacin treatment, 
whereas it was unchanged in untreated and PEG400-treated mice (Figure 3.10 A). There 
was no significant change in Observed species (Figure 3.10 B). Therefore, indomethacin 
increased fecal microbial diversity 6 hours after administration. 
3.3.9 Fecal microbiota composition is altered by indomethacin treatment 
Collection of fecal pellets from the same mouse before and after indomethacin treatment 
revealed within-individual compositional changes (Figure 3.11 A).  Fecal microbial 
communities at 0h and 6h are overlapping with each other in Untreated and PEG400 
groups, but formed separated clusters in indomethacin group. 
Indomethacin treatment induced a significant decrease of the abundance of Bacteroidetes 
(Figure 3.11 B) as well as a significant increase of Firmicutes (Figure 3.11 B) in the feces. 
However, no change occurred in untreated or PEG400-treated mice. 
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Figure 3.11 Indomethacin induces longitudinal changes in fecal microbiota 
composition. (A) Principal coordinates analysis (PCoA) of unweighted UniFrac 
distances was used to compare the fecal microbial communities at 0h (black) versus 6h 
(blue) of untreated (left), PEG400 (middle), and indomethacin (right) groups. Each point 
represents a sample. Fecal microbial communities at 0h and 6h are overlapping in 
untreated and PEG400 groups, whereas they are separated in the indomethacin group. (B) 
The relative abundance of Bacteroidetes is decreased at 6h (blue) after indomethacin 
treatment. (C) The relative abundance of Firmicutes is increased at 6h (blue) after 
indomethacin treatment. ** p < 0.01 by multiple t test, FDR corrected. N=19-20/group. 
Mean ± S.E.M. shown. 
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Figure 3.12 Indomethacin alteres genera abundances in fecal microbiota. There was 
a decrease in the relative abundance of S24-7 (family), and increases in those of 
Ruminococcus, Lachnospiraceae sp., Lachnospiraceae sp., rc4-4, and Anaeroplasma at 
6h (blue). * p < 0.05, ** p < 0.01, *** p < 0.001 by QIIME analysis, FDR corrected. 
N=19-20/group. Mean ± S.E.M. shown. 
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Examination at lower taxonomic levels also revealed indomethacin-induced changes in 
fecal microbiota (Figure 3.12). For example, S24-7 spp., a Bacteroidetes, was decreased 
significantly in indomethacin-treated mice. In parallel, some Firmicutes were 
significantly increased in indomethacin-treated mice, including Ruminococcus, 
Lachnospiraceae, and rc4-4, as were Anaeroplasma, a genus of Tenericutes. These taxa 
were not altered in untreated or PEG400-treated mice. 
The abundance of Clostridiales spp., a genus of Firmicutes, was increased in both 
PEG400- and indomethacin-treated mice at 6h (Figure 3.13 A), consistent with a vehicle 
effect. By contrast, the abundance of Ruminococcaceae spp., another genus of Firmicutes, 
was decreased in PEG400-treated mice but increased in indomethacin-treated mice 
(Figure 3.13 B). This indicates that indomethacin may upregulate this genus, an effect 
great enough to counteract the downregulation by PEG400. The abundance of 
Lactobacillus, a genus of Firmicutes, was increased significantly in PEG400-treated mice, 
yet was not altered in untreated or indomethacin-treated mice (Figure 3.13 C, left), 
Similarly, Oscillospira, a genus of Firmicutes, was decreased in PEG400-treated mice 
only (Figure 3.13 C, right). 
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Figure 3.13 Vehicle effect on fecal microbiota composition. (A) The relative 
abundances of Clostridiales spp. is increased in both PEG400 and indomethacin groups 
at 6h. (B) The relative abundance of Ruminococcaceae spp. is decreased in PEG400 
group but increased in indomethacin group at 6h. (C) PEG400 induced an increase of 
Lactobacillus (left) and a decrease of Oscillospira (right), whereas there is no change in 
untreated or indomethacin groups. * p < 0.05, ** p < 0.01, *** p < 0.001 by QIIME 
analysis, FDR corrested. N=19-20/group. Mean ± S.E.M. shown. 
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3.4 Discussion 
The selected dose and treatment of indomethacin resulted in detectable systemic drug 
exposure; it was present in luminal content and along the mucosa of the small intestine 
and large intestine and was measured in plasma, urine and feces. Reflective of its 
mechanism of analgesic and anti-inflammatory action, this dose of indomethacin 
suppressed endogenous biosynthesis of prostaglandins derived primarily from COX-1 
(PGD2 and Tx) and COX-2 (PGI2 and PGE2) (McAdam et al. 1999, Ricciotti, FitzGerald 
2011), as reflected by urinary excretion of their major metabolites. Indomethacin at the 
dose selected also resulted in small intestinal damage in mice, reminiscent of the 
enteropathy caused by NSAIDs in humans (Allison et al. 1992, Smale et al. 2001). 
We showed that only one single oral dose of indomethacin was sufficient to perturb the 
intestinal microbiota, specifically within the cecum, large intestine and feces. 
Indomethacin-induced effects were less evident in the small intestine. We have shown 
that microbiota composition in the small intestine has higher inter-individual variance 
(Figure 2.2), which may limit the ability to detect the impact of interventions. It is 
possible that (i) indomethacin has no effect in small intestine at all due to the rapid 
turnover in the local environment; (ii) indomethacin-induced changes are too small to 
overcome the inter-individual differences for detection. Therefore, impacts in the small 
intestine may remain difficult to interpret for now.  
Indomethacin induced expansion of Peptococcaceae and Erysipelotrichaceae in the large 
intestine. Peptococcaceae are Gram-positive anaerobic bacteria of Firmicutes. 
 63 
 
Environmental cultures of Peptococcaceae originated from soil and groundwater have 
been shown to mediate anaerobic benzene biodegradation (van der Zaan et al. 2012, Luo 
et al. 2014, Cupples 2011), and its abundance is significantly increased when grown on 
benzene (Luo et al. 2014). It is hence possible that exogenous indomethacin provides an 
extra substrate and promoted the expansion of Peptococcaceae in the GI tract. The 
physiological role of Peptococcaceae is poorly understood, although it is commonly 
found in the mouth and intestinal and respiratory tracts of human and other animals 
(Rogosa 1971). Erysipelotrichaceae is a Gram-positive bacterial family of Firmicutes. It 
has been shown to be positively associated parenteral nutrition associated liver injury by 
activating TLR2 signaling pathways (Harris et al. 2014). More recently, blooming of 
Erysipelotrichaceae has also been associated with obesity (Zhang et al. 2009), colorectal 
cancer (Zhu et al. 2014, Chen et al. 2012), and Crohn’s disease (Kaakoush et al. 2015). 
Elevation of these pro-inflammatory bacteria in the intestine, together with small 
intestinal damage developed in a later stage (Figure 3.4) may provide a link between 
indomethacin-induced compositional changes along the GI tract and the GI toxicity of 
indomethacin. 
Indomethacin also induced pro-inflammatory shifts in the composition of fecal 
microbiota, for example, a significantly increased ratio of Firmicutes to Bacteroidetes.  
This shift has been previously reported in genetically obese mice (Ley et al. 2005, 
Turnbaugh et al. 2006), obese children (Bervoets et al. 2013), and obese adults (Ley et al. 
2006b). Besides, the decrease of S24-7, a family of Bacteroidetes, such as induced here 
by indomethacin, has been observed in a mouse model of colorectal cancer (Liang et al. 
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2014), as well as in mice with high fat diet-induced obesity (Evans et al. 2014). 
Lachnospiraceae, also upregulated by indomethacin, have been associated with lupus 
(Zhang et al. 2014a), drug-induced liver toxicity (Xu et al. 2015). It also contributes to 
the development of obesity and diabetes in genetically susceptible mice (Kameyama, Itoh 
2014).  
The indomethacin vehicle, PEG400, was found to have an effect on microbial diversity 
and composition (Harrell et al. 2012). In the distal intestine, PEG400 caused decreased 
diversity in luminal content and increased diversity in mucosal tissue; the abundances of 
fecal Clostridiales spp. and Lactobacillus were increased while the abundance of 
Oscillospira was decreased (Figure 3.13). Possible explanations for the vehicle effect 
include a water-absorbing dilutional effect and/or a “flushing” effect carrying upstream 
luminal bacteria down to the large intestine. Similarly, Golytely (PEG 3350) has been 
previously reported to cause changes in the mucosal-associated microbiota in the human 
colon (Harrell et al. 2012). The trial design, however, allowed us detect indomethacin 
effects independent of vehicle effects. 
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Chapter 4 The intestinal microbiota affects the 
pharmacokinetics of indomethacin 
4.1 Introduction 
NSAIDs show considerable inter-individual variation in pharmacokinetics in humans 
(Brune 1985, Brune 1987). This may contribute significantly to the observed inter-
individual differences in the efficacy and risk of GI complications from indomethacin. 
Deciphering the sources of such variability is a critical step in developing a more 
personalized approach to using these drugs more safely and efficaciously.  
Intestinal bacteria have been shown to mediate the biotransformation of over 30 approved 
drugs by directly or indirectly influencing their metabolism (Clayton et al. 2009, Okuda 
et al. 1998, Saha et al. 1983, Meinl et al. 2009, Sousa et al. 2008).  Interestingly, the 
composition of intestinal microbiota shows great inter-individual variability in both the 
presented species and the proportions of bacterial lineages (Arumugam et al. 2011a, 
Eckburg et al. 2005). Therefore, it is conceivable that bacteria play a role in the 
heterogeneity of the human response to indomethacin by modulating its metabolism and 
hence affecting its pharmacokinetics.  However, despite a growing appreciation of the 
importance of intestinal microbiome, few studies have addressed its importance in 
indomethacin pharmacometabolomics. 
The metabolism of indomethacin involves enterohepatic circulation (Harman et al. 1964). 
Briefly, indomethacin is glucuronidated in the liver by UDP-glucuronosyltransferases 
(UGTs) (Figure 4.1) and the glucuronide is delivered to the small intestine with bile acids. 
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In the intestine, indomethacin glucuronide is de-conjugated to the parent drug which is 
then reabsorbed into the circulation (Figure 4.1). Previously, bacterial β-glucuronidase 
expressed by intestinal microbiota has been shown to contribute to the GI damage 
inflicted by the anticancer drug CPT-11 (Roberts et al. 2013) and by several NSAIDs, 
including diclofenac, indomethacin and ketoprofen (Saitta et al. 2014).  
 
Figure 4.1 Chemical structures of indomethacin and indomethacin glucuronide. 
Conversion of indomethacin to indomethacin glucuronide is catalyzed by UDP-
glucuronosyltransferase (UGT). The reverse de-conjugation process is catalyzed by β-
glucuronidase. 
 
Antibiotics have been widely used in research with animal models to investigate the 
physiological role of the normal microbiota. Using an antibiotic cocktail has provided 
evidence for the involvement of intestinal microbiota in various physiological and 
pathophysiological processes (Rakoff-Nahoum et al. 2004, Iida et al. 2013). Neomycin 
mainly targets Gram-negative bacteria and causes misreading of t-RNA, hence 
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synthesizing nonfunctional protein by binding to the bacterial 30S ribosomal subunit. 
Vancomycin mainly targets Gram-positive bacteria and inhibits bacterial cell-wall 
biosynthesis. Both neomycin and vancomycin are poorly absorbed from the 
gastrointestinal tract (Moellering 1984, Breen et al. 1972), and hence cause minimal 
interference with the host.  
In this study, we use antibiotic treatment in mice as the model to address our hypotheses 
that the intestinal microbiota play a role in indomethacin pharmacokinetics and that this 
effect partially involves bacteria-mediated de-glucuronidation of indomethacin conjugate.  
4.2 Materials and Methods 
4.2.1 Animals  
All C57BL/6 mice were purchased from the Jackson Laboratory and housed in our 
animal facility for at least 2 weeks before experiment. Male mice 10-14 weeks of age 
were used for all experiments. All animals were fed at libitum with regular chow diet 
(5010, LabDiet) for the course of study. Mice were kept under 12-hour light/12-hour dark 
(LD) cycle, with lights on at 7am and off at 7pm. Experimental protocols were reviewed 
and approved by the Institute for Animal Care and Use Committee at the University of 
Pennsylvania. 
4.2.2 Study design 
Mice were housed individually throughout the experiment. Mice were treated as 
previously described. Briefly, mice received either control (water) or an antibiotic 
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cocktail (1 g/L neomycin and 0.5 g/L vancomycin) for 5 days during which they have 
free access to a regular chow diet (Shen et al. 2015). Water for both treatment groups was 
spiked with aspartame. Body weight, food intake, and water intake of each mouse were 
followed daily throughout the study. Fecal pallets from each individual mouse were 
collected before, during, and after indomethacin treatment for microbiota composition 
analysis. 10mg/Kg indomethacin (in PEG400) was administered to mice in both 
antibiotic-treated and control groups at 12pm.  
For the evaluation of indomethacin pharmacokinetics, blood was sampled from mouse 
tail veins at 1, 2, 4, 6, 8, 24, 30, 48 hours post indomethacin administration. Plasma was 
collected and stored at -80°C for the measurement of indomethacin using liquid 
chromatography/mass spectrometry (LC/MS).  
For the evaluation of glucuronidation, urine and fecal pellets were collected with the use 
of metabolic cages at 4, 8, 12, and 24 hours post indomethacin administration. Samples 
were stored at -80°C for the measurement of indomethacin and its metabolites using 
LC/MS. 
4.2.3 Sample preparation for mass spectrometric analysis of indomethacin 
Plasma samples (~10 μl) were mixed with 50 μl indomethacin internal standard (500 ng 
in ACN), 20 μl formic acid and 900 μl H2O. Samples were vortexed and centrifuged 
before solid phase extraction (SPE).  
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4.2.4 Sample preparation for mass spectrometric analysis of indomethacin 
metabolites 
Urine samples (20 μl) were mixed with 40 μl indomethacin internal standard (40 ng in 
ACN), 400 μl sodium acetate and 10 μl β-Glucuronidase from Helix pomatia.  After 
hydrolysis at 37°C for 4 h, the samples were mixed with 20 μl formic acid and 500 μl 
H2O. Another urine sample (20 μl) was mixed with 40 μl indomethacin internal standard 
(40 ng in ACN), 20 μl formic acid and 900 μl H2O without hydrolysis treatment. Dry 
stool samples were weighed before extraction with 1.7 mL of sodium acetate (0.2M, 
pH=5.0) using stainless steel-beads and a TissueLyser homogenizer (Qiagen, Valencia, 
CA, USA).  The supernatant after centrifugation was divided to two aliquots. One aliquot 
was mixed with 40 μl indomethacin internal standard (40 ng in ACN), 20 μl formic acid 
and 300 μl H2O before SPE. The other aliquot was mixed with 40 μl indomethacin 
internal standard (40 ng in ACN) and 15 μl β-Glucuronidase. The β-Glucuronidase 
hydrolysis was performed at 37°C for 4 h. The samples after hydrolysis were then mixed 
with 20 μl of formic acid and 300 μl H2O before SPE. 
4.2.5 Solid-phase extraction  
Solid-phase extraction (SPE) was performed as described in Chapter 3(3.2.6). 
4.2.6 Calibration curves for mass spectrometric analysis of indomethacin 
Calibration curves for indomethacin analysis were prepared as described in Chapter 3 
(3.2.7). 
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4.2.7 Calibration curves for mass spectrometric analysis of indomethacin 
metabolites 
 To calculate the precise relative amount of indomethacin and its metabolite, standard 
curves were prepared in mouse urine for indomethacin, and acyl-β-D-glucuronide 
indomethacin (Santa Cruz Biotechnology, Dallas, Texas, USA). Individual stock 
solutions of each compound (100 ng/µl) were prepared in ACN and stored at -80°C. 
Working solutions were prepared by mixing equal amounts of corresponding stock 
solutions and performing serial dilutions with ACN. Seven point calibration samples (0, 
0.032, 0.16, 0.8, 4, 20 and 100 ng/µl) for indomethacin and its metabolite were prepared. 
One large urine sample was obtained from mice without exposure to indomethacin. For 
each sample, 40 µl of (1 ng/µl) d4-Indomethacin (Santa Cruz Biotechnology, Dallas, 
Texas, USA), 10 µl calibration standards were added to 20 mouse urine. The samples 
were extracted by SPE before LC/MS. 
4.2.8 Liquid chromatography/mass spectrometry for indomethacin 
Indomethacin was measured by LC/MS as described in Chapter 3 (3.2.8). 
4.2.9 Liquid chromatography/mass spectrometry for indomethacin metabolites 
Indomethacin metabolites were measured using a TSQ Quantum Ultra™ triple 
quadrupole mass spectrometer (Thermo Scientific, Wilmington, DE, USA) equipped with 
an ESI ion source. The Mass Spectrometer was connected to a Thermo Scientific Accela 
HPLC Systems and equipped with a PAL auto sampler and thermocontroller (set at 4°C). 
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The CSH C18 Column (2.1 mm X 150 mm, 130Å, 1.7 µm, Waters) was used at a 
constant 40°C. The mobile phase (A) (90% H2O/10% (B),  0.2% acetic acid) and mobile 
(B) (90% ACN/10% methanol) was used at a flow rate of 350 μl/min with a binary 
gradient (0-12 min, 10-50% B; 12-12.5 min, 50-100% B; 12.5-16 min, 100% B; 16.2-20 
min, 10% B). Mass spectrometry was performed in negative mode. The transition for 
indomethacin and d4-indomethacin are 355.9>311.9 and 359.9>315.9, respectively. The 
transition for O-desmethyl indomethacin and acyl-β-D-glucuronide indomethacin are 
298.0>256.1 and 533.1>193.3, respectively. Both Q1 and Q3 were operated at 0.7 m/z 
FWHM. Peak area ratios of target analytes to d4-indomethacin internal standards were 
calculated by Xcalibur Quan software. The data were fitted to the calibration curves to 
calculate the precise relative amount of indomethacin and its metabolites.  
4.2.10 DNA extraction for microbiota composition analysis 
DNA extraction was performed as described in Chapter 2 (2.2.3). 
4.2.11 16S rRNA quantification 
Quantification of 16S rRNA was performed by real-time PCR as described in Chapter 2 
(2.2.4). 
4.2.12 V1-V2 16S rRNA region amplification and sequencing 
16S rRNA gene amplification was performed as described in Chapter 2 (2.2.5). 
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4.2.13  Bioinformatics 
Sequence data were processed with QIIME v 1.8.0 (Caporaso et al. 2010c) using default 
parameters, as described in Chapter 2 (2.2.6).  
4.2.14 Pharmacokinetic analysis 
Plasma indomethacin concentrations at 1, 2, 4, 6, 8, 24, 30, 48 hours post administration 
were plotted against time to generate the “plasma indomethacin concentration versus time 
curve”. The area under the curve (AUCtotal) was then calculated according to the 
trapezoidal rule and the elimination rate constant (Kel) was obtained as the slope value. 
The half-life (t1/2) was calculated as 𝑡1/2 = 𝑙𝑛2/𝑘𝑒𝑙. The apparent volume of distribution 
Vd was calculated as 𝑉𝑑 = 𝑑𝑜𝑠𝑒/𝐶0. C0 was extrapolated using the plasma drug 
concentration versus time curve. The oral clearance Cl was calculated as 𝐶𝑙 =
𝑑𝑜𝑠𝑒/𝐴𝑈𝐶𝑡𝑜𝑡𝑎𝑙.  
4.3 Results  
4.3.1 Antibiotic-treatment depletes the microbiota in the intestine 
The 16S rRNA copy numbers mice receiving control water was relatively stable 
throughout the study. However, the 16S rRNA copy numbers in feces were reduced by 
99.9% in mice receiving antibiotic cocktail after 5 days (Figure 4.2 A). After cessation of 
antibiotic cocktail, the 16S rRNA copy number increased slightly, but was still reduced 
by 93.8% on Day 6 and 87.5% on Day 7 (Figure 4.2 A).  
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Microbial diversity analysis revealed a significant decrease, starting at Day 4. The 
observed species was reduced by 86.7% on Day 4, 89.6% on Day 5, 91.8% on Day 6, and 
97.2% on Day 7 (Figure 4.2 B).  
 
Figure 4.2 Antibiotic-treatment reduces the gut microbial load in mice. Mice were 
treated with the antibiotic cocktail (Abx, neomycin and vancomycin) or control water 
(Con) for 5 days (blue-shaded area) and their fecal microbiota compositions over time 
were analyzed using 16S rRNA profiling. (A) Longitudinal analysis of 16S rRNA gene 
copies per gram of feces reveals a significant reduction in microbial load in Abx group 
(red). (B) Longitudinal analysis of Observed Species reveals decreased microbial 
richness in Abx group (red). ** p < 0.01, *** p < 0.001 by multiple t test, FDR corrected. 
N=4-6/group. Mean ± S.E.M. shown. 
 
During antibiotic treatment, body weight, food intake, and water intake were measured 
daily. As shown in Figure 4.3, antibiotic-treated mice had comparable body weight, food 
intake and water intake over the time-course studied with control mice. Higher water 
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intake on Day 5 in antibiotic-treated mice was attributed to water bottle movement when 
the facility staff changed the cages.  
 
Figure 4.3 Body weight, food intake, and water intake are not affected by antibiotic-
treatment in C57BL/6 mice. (A) Body weight, (B) Food intake, and (C) Water intake 
are not affected by antibiotic treatment. Note: on day 5 animal cages were changes by 
facility staff and the movement caused water loss. N=6/group. Mean ± S.E.M. shown. 
 
4.3.2 Microbiota composition is altered by antibiotic-treatment 
Besides comparable microbial biomass and diversity prior to antibiotic treatment, all 
mice had similar composition of fecal microbiota as well (Figure 4.4, Day 0). After 5 
days of antibiotic treatment, mice showed significantly shifted the composition of the 
fecal microbiota, with a reduction in Bacteroidetes and Firmicutes, and a concomitant 
expansion of Proteobacteria (Figure 4.4). 
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Figure 4.4 Antibiotic treatment alteres the microbiota composition. Heat map of the 
longitudinal analysis of bacterial lineages detected in feces of control (light green) or 
antibiotic treated (dark green) mice before (Day 0) and after (Day 5, 6, and 7) treatment. 
Each column represents one individual mouse of the time and treatment group indicated. 
Microbial composition is shifted in the Abx group but is stable in Con group. The 
proportions of bacterial lineages are indicated by the color code to the right. 
 
4.3.3 Indomethacin pharmacokinetics are altered in antibiotic-treated mice 
In antibiotic-treated mice, the oral clearance of indomethacin was increased by 19.6% 
(Figure 4.5 A), and the elimination rate constant Kel was increased by 55.2% (Figure 4.5 
B), indicating an increased elimination of indomethacin. Consistently, the total area-
under-the-curve (AUCtotal) of indomethacin, which is a measurement of total drug 
 76 
 
exposure, was decreased by 16.8% in antibiotic-treated mice (Figure 4.5 C). The half-life 
(t1/2) of indomethacin was decreased by 37.5% (Figure 4.5 D), and the apparent volume 
of distribution (Vd) of indomethacin was decreased by 46.1% (Figure 4.5 E) in antibiotic-
treated mice.  
 
Figure 4.5 The pharmacokinetics of indomethacin is altered in antibiotic-treated 
mice. In antibiotic-treated mice (red), indomethacin has increased (A) oral Clearance and 
(B) elimination rate constant (Kel), as well as decreased (C) area under the curve 
(AUCtotal), (D) half-life (t1/2), and (E) apparent volume of distribution (Vd). * p < 0.05, ** 
p < 0.01 by Mann-Whitney test. N=6/group. Mean ± S.E.M. shown. 
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The variances of the total area-under-the-curve (AUCtotal), half-life (t1/2), and the apparent 
volume of distribution (Vd) of indomethacin were significantly smaller in antibiotic-
treated mice than in control mice (p= 0.01 for AUCtotal, p=0.04 for t1/2, and p=0.006 for 
Vd by F test), suggesting antibiotic-treatment reduced the source of variation in response 
to indomethacin.  
4.3.4 Indomethacin glucuronidation in antibiotic-treated mice is impaired 
Detection of indomethacin and indomethacin-glucuronide was confirmed by incubating 
samples with or without β-glucuronidase.  
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Figure 4.6 Representative spectra of LC/MS measurements of indomethacin and its 
metabolites. (A) Samples without β-glucuronidase incubation. The peak denoting Acyl-
b-D-glucuronide Indomethacin (indomethacin glucuronide) was larger, whereas the peak 
denoting Indomethacin was smaller. (B) Samples with β-glucuronidase incubation. The 
peak denoting Acyl-b-D-glucuronide Indomethacin was diminished, whereas the peak 
denoting Indomethacin was increased.d4-indomethacin is the internal standard for 
indomethacin.  
 79 
 
As shown in the representative spectra (Figure 4.6), there was a large peak corresponding 
to indomethacin glucuronide and a smaller peak corresponding to indomethacin in the 
control samples, whereas after incubation with β-glucuronidase, the peak of indomethacin 
glucuronide was diminished and that of indomethacin greatly increased. This verified our 
mass spectrometry detection of indomethacin and its metabolites.  
This shift of decreased indomethacin concentration and increased indomethacin 
glucuronide concentration was detected in each of the samples we studied as shown in 
Figure 4.7. Indomethacin glucuronide was readily detected in the absence of incubation 
with β-glucuronidase. However, after incubation with β-glucuronidase, only 
indomethacin was detected in samples, indicating the breakdown of indomethacin 
glucuronide by β-glucuronidase. 
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Figure 4.7 Proportions of indomethacin and indomethacin glucuronide in samples 
with or without β-glucuronidase incubation. (A) Urine samples of both control mice 
(Con) and antibiotic-treated mice (Abx). (B) Fecal samples of both control mice (Con) 
and antibiotic-treated mice (Abx). The proportions of indomethacin glucuronide (red) are 
smaller with β-glucuronidase added. Similarly, the proportions of indomethacin (blue) are 
larger with β-glucuronidase added. Each graph shows the longitudinal changes in one 
mouse. N=6/group. 
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Figure 4.7 also showed that antibiotic-treated mice had more indomethacin glucuronide 
in both urine and feces compared to control mice, indicating the glucuronidation level of 
indomethacin was altered due to the depletion of intestinal microbiota. To address this 
question, we compared the ratio of indomethacin-glucuronide to indomethacin in mice 
pretreated with or without the antibiotic cocktail.  
 
Figure 4.8 Glucuronidation level of indomethacin in antibiotic-treated mice are 
altered. (A) The ratio of indomethacin-glucuronide to indomethacin in urine of control 
mice (blue) and antibiotic-treated mice (red) following indomethacin administration. (B) 
The ratio of indomethacin-glucuronide to indomethacin in urine of control mice (blue) 
and antibiotic-treated mice (red) following indomethacin administration. In both urine 
and feces, the ratio is higher in antibiotic-treated mice. * p < 0.05, ** p < 0.01 by Mann-
Whitney test. N=6/group. Mean ± S.E.M. shown. 
 
In urine, the ratio was significantly higher in antibiotic-treated mice for the first 12 hours 
following indomethacin administration (Figure 4.8 A). The ratio in antibiotic-treated 
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mice is 15 fold at 4h, 2.5 fold at 8h, and 1.7 fold at 12h of that in control mice. In feces, 
indomethacin-glucuronide was barely detectable in control mice, yet was steadily 
detected in antibiotic-treated mice (Figure 4.8 B). 
Indomethacin suppressed urinary prostanoid metabolites irrespective of treatment with 
the antibiotic cocktail (Figure 4.9). PGD-M and PGI-M levels were reduced by 
indomethacin in a time-dependent fashion in both control mice and antibiotic-treated 
mice. However, ANOVA revealed a significant effect due to antibiotic treatment in the 
more abundant urinary PGE-M and Tx-M concentrations. Unlike in control mice, where 
both metabolites were reduced time-dependently, in antibiotic-treated mice, both 
metabolites were detectably suppressed to a lesser degree by indomethacin and their 
concentration started to recover faster in antibiotic-treated mice compared to control mice 
(Figure 4.9). The reduced inhibitory effect was attributable to the reduced distribution 
and exposure to indomethacin in antibiotic-treated mice. Taken together, the β-
glucuronidase-catalyzed de-glucuronidation was impaired due to antibiotic-treatment, 
partially suppressing the inhibitory effect of indomethacin on COX enzymes.  
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Figure 4.9 Efficacy of indomethacin in antibiotic-treated mice is altered. Urinary 
prostanoid metabolites were analyzed with LC/MS and values are corrected by creatinine. 
In control mice (blue), all metabolites were reduced time-dependently. In Abx mice (red) 
PGD-M and PGI-M remained suppressed 24 hour after indomethacin, whereas PGE-M 
and Tx-M concentrations recovered more quickly. Two-way ANOVA revealed 
significant effect of time in PGD-M (p=0.001) and PGI-M (p=0.0004), and significant 
antibiotic effect of PGE-M (p<0.0001) and Tx-M (p=0.0002).In abx mice, PGE-M was 
higher mice at 24h, and Tx-M was higher at 4h and 24h. N=6/group. * p < 0.05, ** p < 
0.01 by multiple  comparison test, adjusted. Mean ± S.E.M. shown. 
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4.4 Discussion 
Indomethacin undergoes enterohepatic circulation (Harman et al. 1964).  It is 
glucuronidated in the liver by UDP-glucuronosyltransferases (UGTs) and the glucuronide 
is delivered to the small intestine with bile acid. The intestinal bacteria have been shown 
to have functional β-glucuronidase (Roberts et al. 2013). Here we show that when the 
intestinal microbiota was suppressed by an antibiotic cocktail, the level of de-
glucuronidation was significantly compromised (Figure 4.8), consistent with involvement 
of intestinal bacteria in the catalysis of this reaction. Therefore, the intestinal microbiota, 
by playing a role in the metabolism of indomethacin, have an impact on indomethacin 
pharmacokinetics. When bacteria-mediated de-glucuronidation was impaired, 
indomethacin reabsorption into the circulation was reduced, consistent with a shortened 
half-life and reduced drug exposure (Figure 4.5). Suppression by indomethacin of the 
urinary excretion of the most abundant prostanoid metabolites - Tx and PGE - was 
detectably reduced in antibiotic treated mice, suggesting that concomitant antibiotic 
treatment may undermine the efficacy of this NSAID. It may also explain the attenuated 
enteropathy associated with indomethacin in rats pretreated with antibiotics (Koga et al. 
1999a). 
The association of the genetic variation of Cytochrome P450 2C9 (CYP2C9) with the GI 
complications of indomethacin is unaddressed, although indomethacin clearance is 
largely catalyzed by CYP2C9 (Nakajima et al. 1998). A small study reported that there is 
no clinically significant relationship between CYP2C9 genotype and risk of gastric 
ulceration resulting from NSAID usage (Martin et al. 2001). However, its conclusion is 
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limited by the small sample size and the miscellaneous NSAIDs. Due to the lack of 
evidence, pharmacogenetic testing for indomethacin was not clinically recommended 
(Wyatt, Pettit & Harirforoosh 2012).  
Since the intestinal microbiota are variable amongst individuals (Arumugam et al. 2011b, 
Bushman, Lewis & Wu 2013), intestinal microbiota-mediated metabolism of 
indomethacin may be a potential factor underlying the inter-individual differences of 
indomethacin pharmacokinetics (Brune 1985, Brune 1987). Indeed, we found that 
antibiotic-treated mice have significantly less inter-mouse variability of half-life and 
volume of distribution compared to control mice (Figure 4.5 D, E). Despite this work still 
being at an early in the stage, consideration should be given to intestinal microbiota-
mediated biotransformation of drugs during drug development as at least 30 drugs are 
directly or indirectly affected by intestinal bacteria (Clayton et al. 2009, Okuda et al. 
1998, Saha et al. 1983, Meinl et al. 2009, Sousa et al. 2008). 
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Chapter 5 Rhythmicity of the intestinal microbiota is regulated 
by gender and the host circadian clock 
5.1 Introduction 
Despite influences from host genetics (Benson et al. 2010b), ageing (Biagi et al. 2010), 
use of antibiotics (Jernberg et al. 2010), lifestyle (Annalisa et al. 2014), pet ownership 
(Song et al. 2013), and concomitant disease (Zhao 2013, Wu, Bushman & Lewis 2013), 
the intestinal microbial community is largely shaped by diet (Wu et al. 2011) and the 
impact has been well established in both humans and mice (David et al. 2014, De Filippo 
et al. 2010).  
In addition to the type of food consumed (Daniel et al. 2014), the feeding behavior of the 
host also influences the microbiota. For instance, a 24-hour fast increases the abundance 
of Bacteroidetes and reduces that of Firmicutes in mouse cecum, without altering the 
communal microbial diversity (Crawford et al. 2009). Bacteroidetes are also dominant in 
the microbiota of the fasted Burmese python, while ingestion of a meal shifts the 
intestinal composition towards Firmicutes (Costello et al. 2010).  
It has been widely appreciated that the pharmacokinetics of orally dosed indomethacin 
shows circadian variation both in humans and in rats. For instance, a reduced peak in the 
plasma concentrations of indomethacin associated with a prolonged apparent half-life (t1/2) 
and with an increased formation of indomethacin metabolites was observed in patients 
dosed in the evening compared to those dosed in the morning or at noon (Guissou et al. 
1983). Interestingly, a double-blind clinical study showed that indomethacin caused less 
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undesirable effects in patients dosed in the evenings compared to those dosed in the 
morning (Levi, Le Louarn & Reinberg 1985).  Moreover, rats dosed during the rest phase 
have significantly lower initial indomethacin plasma concentrations (C0) and area under 
the curve (AUC), as well as significantly increased distribution volume (Vd) and total 
metabolic clearance (ClT) compared to rats dosed during the active phase (Guissou et al. 
1987).  
We observed that the intestinal microbiota affects the pharmacokinetics and 
pharmacodynamics of indomethacin in mice partially via bacteria-mediated de-
glucuronidation (Chapter 4). A recent study used a functional metagenomic approach and 
revealed a class of β-glucuronidases that may be part of a functional core with major 
health implications (Gloux et al. 2011). Therefore, it is worthwhile to investigate whether 
the effect of intestinal microbiota on indomethacin pharmacokinetics and efficacy is a 
potential factor contributing to the chronopharmacology of indomethacin via diurnal 
oscillation in its composition.  
In this study, we address our hypotheses that the microbial composition oscillates 
diurnally and this oscillation is influenced by the host clock.  
5.2 Materials and Methods 
5.2.1 Animals 
All C57BL/6 mice and Bmal1 KO mice were raised in our animal facility. Mice 10-14 
weeks of age were used for all experiments. All animals were fed at libitum with regular 
chow diet (5010, LabDiet) for the course of study. Mice were kept under 12-hour 
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light/12-hour dark (LD) cycle, with lights on at 7am and off at 7pm. Experimental 
protocols were reviewed and approved by the Institute for Animal Care and Use 
Committee at the University of Pennsylvania.  
5.2.2 Study design 
Study 1: Microbial oscillation in WT mice. C57BL/6 mice were bred in our facility and 
caged according to litter and gender. 7 male mice (housed in two cages with 3 in one cage 
and 4 in the other) and 7 female mice (housed in two cages with 3 in one cage and 4 in 
the other) were studied. Fecal pellets from each mouse were sampled every 4 hours for 48 
hours (2 light-dark cycles, 13 time points), as illustrated in Figure 5.1. A total of 182 
samples were collected for microbiota composition analysis by pyrosequencing. 
Sequencing yielded 360,809 reads.  
 
Figure 5.1 Schematic diagram illustrating the study design. Fecal pellets were 
longitudinally sampled from individual mice at 11pm, 3am, 7am, 11am, 3pm, and 7pm 
for 2 continuous light-dark cycles as indicated by the red dot. All fecal pellets were 
weighed and stored at -80°C until use. 
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Study 2: Effect of Bmal1 deletion on microbial oscillation in mice. Homozygous Bma1 
KO mice were established in our mouse colony by mating heterozygous pairs. Bmal1 KO 
mice were housed separately from the littermate wild type (WT) controls as soon as the 
genotype was confirmed to minimize the influence of corporophagia (Deloris Alexander 
et al. 2006). Four female (housed in two cages with 2 in each) and two male (housed in 
two cages with 1 in each) Bmal1 KO mice as well as two female (housed in two cages 
with 1 in each) and three male (housed in two cages with 2 in one cage and 1 in the other) 
littermate control mice were studied. Fecal pellets from each mouse were sampled every 
4 hours for 48 hours, as illustrated in Figure 5.1. A total of 143 samples were collected 
for microbiota composition analysis by pyrosequencing.  
5.2.3 DNA extraction for microbiota composition analysis 
DNA extraction was performed as described in Chapter 2 (2.2.3). 
5.2.4 16S rRNA quantification 
Quantification of 16S rRNA was performed by real-time PCR as described in Chapter 2 
(2.2.4). 
5.2.5 V1-V2 16S rRNA region amplification and sequencing 
16S rRNA gene amplification was performed as described in Chapter 2 (2.2.5). 
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5.2.6  Bioinformatics 
Sequence data were processed with QIIME v 1.8.0 (Caporaso et al. 2010c) using default 
parameters, as described in Chapter 2 (2.2.6).  
5.2.7 Statistical analysis 
Statistical tests for rhythmicity were performed using JTK_CYCLE algorithm as 
previously described (Hughes, Hogenesch & Kornacker 2010) with a period-length 
window of 20–28 hr. Comparisons of the relative abundances of bacterial taxons were 
done by Mann-Whitney test. Paired tests were performed where appropriate. p-values 
were corrected for multiple comparisons using the procedure of Benjamini and Hochberg 
to control for a false discovery rate (FDR) of less than 5%. PERMANOVA (McArdle, 
Anderson 2001) procedure was applied based on pairwise UniFrac distance to assess the 
sources of variation, and p-values were obtained using permutation tests.  
5.3 Results  
5.3.1 Microbiota composition oscillates diurnally 
The relative abundances of Bacteroidetes and Firmicutes, the two most abundant 
components of mammalian microbiota, varied during the light-dark cycle (Figure 5.2). 
The average abundance of Bacteroidetes was higher at 11pm (66%) and 11am (60%) and 
lower at other times, whereas that of Firmicutes was higher at 3am (45%) and 7am (45%) 
and lowest at 11pm (29%).  
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Figure 5.2 Bar graphs of average relative abundances of bacterial phyla of WT mice. 
Fecal pellets from male and female mice housed under normal light-dark cycle were 
collected every 4 hours for 48 hours. Microbiota structure in fecal samples of combined 
genders at various sampling time points during the day were plotted. Lineages were 
identified by the uclust consensus taxonomy classifier. 
 
We used the JTK_CYCLE algorithm (Hughes, Hogenesch & Kornacker 2010) to test 
whether the composition of fecal microbiota exhibited circadian rhythmicity. The fecal 
bacterial load, as measured by the total 16S rRNA gene copy numbers in samples, 
oscillated diurnally during the light-dark cycle both in the group as a whole and when 
segregated by gender (Figure 5.3 A). The bacterial load peaked around 11pm and 
gradually decreased towards the late dark phase until the lowest level was noted around 
7am when the light was on. Male mice had more bacteria overall in feces than female 
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mice, however female mice showed more significant diurnal oscillation (p=2.82E-06) 
than male mice (p= 0.03).  
Diurnal oscillation was also observed in the relative abundance of Bacteroidetes and 
Firmicutes (Figure 5.3 B, C). Bacteroidetes were most abundant at 11pm and least 
abundant at 7am. Firmicutes exhibited a contrasting pattern and accordingly, the ratio of 
Bacteroidetes to Firmicutes exhibited diurnal oscillation (Figure 5.3 D). The average 
gastrointestinal transit time of mice is about 4-5 hours (Kashyap et al. 2013). Hence the 
fecal pellets we sampled are representative of the microbiota of the host 4-5 hours before 
sampling time. As a result, the peak and trough of the relative abundance of Baceroidetes 
in the upper gastrointestinal tract should be around 7pm and 3am, respectively. Similarly, 
the peak and trough of the relative abundance of Firmicutes in the upper gastrointestinal 
tract should be around 3am and 7pm, respectively. The inferred absolute abundance of 
bacterial lineage was calculated by multiplying its relative abundance by the 16S rRNA 
gene copy number in each sample.  
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Figure 5.3 Diurnal oscillation of intestinal microbiota composition in C57BL/6 mice. 
The light phase is indicated as white, the dark phase indicated by grey shading. (A) Fecal 
bacterial load oscillates diurnally in mice both when combined (left) and separated (right; 
male, green; female, orange) by gender, as indicated by 16S rRNA copy numbers 
normalized to sample weight. JTK_ CYCLE revealed p=0.0001 for mice of combined 
genders, p= 0.03 for male mice, and p=2.82E-06 for female mice. (B) Relative abundance 
of Bacteroidetes oscillates diurnally in mice when genders are combined (left) and 
separated (right). JTK_ CYCLE revealed p=0.0001 for combined genders, p= 0.03 for 
male mice, and p=0.0006 for female mice. (C) The relative abundance of Firmicutes 
oscillates in an opposite pattern to Bacteroidetes in mice of combined (left) and separated 
(right) genders. JTK_ CYCLE revealed p=6.29E-05 for mice when genders are combined, 
p= 0.05 for male mice, and p=0.001 for female mice. (D) The ratio of Bacteroidetes to 
Firmicutes oscillates accordingly in mice of combined (left) and separated (right) genders. 
JTK_CYCLE revealed p=5.84E-05 for mice of combined genders, p= 0.04 for male mice, 
and p=0.0009 for female mice. Nmale = 7, Nfemale = 7. Mean ± S.E.M. shown. 
 
Examination of the relative abundances at the genus level revealed more structure in the 
taxonomic oscillation (Figure 5.4). S24-7 spp., a major genus of Bacteroidetes, oscillates 
in the same pattern as Bacteroidetes (Figure 5.3 B). Several abundant genera in 
Firmicutes, including Lachnospiraceae spp., Oscillospira, Ruminococcaceae spp., 
Clostridiales spp., and Clostridia spp., oscillate out of phase with S24-7 spp. 
Anaeroplasma, a Tenericutes, oscillates in phase with Firmicutes. Thus, the composition 
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of microbiota in C57BL/6 mice, both total bacterial load and the abundance of discrete 
bacterial lineages, undergoes diurnal oscillation during the 24-hour light-dark cycle. 
 
Figure 5.4 Diurnal oscillation of genus abundances in C57BL/6 mice. Diurnal 
oscillations during the light-dark cycle were observed in the abundances of S24-7 spp. 
(p=0.016), Lachnospiraceae spp. (p=0.0004), Oscillospira (p=0.0005), Clostridiales spp. 
(p=0.002), Clostridia spp. (p=0.001), and Anaeroplasma (p=0.03), and Ruminococcaceae 
spp. (p=0.003). 
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5.3.2 Bmal1 deletion abolishes the oscillation in microbiota composition 
Fecal pellets were sampled from Bmal1 knock out (KO) mice and their littermate control 
mice every 4 hours for 48 hours, to investigate the effect of Bmal1 deletion.  
 
Figure 5.5 Bar graphs of average relative abundances of bacterial phyla of WT and 
Bmal1 KO mice. (A) Microbiota structure in fecal samples of combined genders of WT 
mice at various sampling time points during the day were plotted. (B) Microbiota 
structure in fecal samples of combined genders of Bmal1 KO mice at various sampling 
time points during the day were plotted. 
 
Circadian rhythms in the microbiota differed in Bmal1 KO mice versus wild type (WT) 
mice (Figure 5.5). In WT mice, the average abundance of Bacteroidetes was highest at 
11pm (76%) lowest at 7am (54%), and that of Firmicutes was highest at 7am (37%) and 
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lowest at 11pm (19%). In contrast, variability in the composition of the microbiota was 
suppressed in Bmal1 KO mice (Figure 5.5 B).  
 
Figure 5.6 Bmal1 deletion abolishes the diurnal oscillation of intestinal microbiota 
composition in mice. (A) The fecal bacterial load in Bmal1 KO mice (red) was slightly 
lower than that in WT mice (blue) but showed a similar fluctuating pattern during the 
light-dark cycle. (B) The ratio of Bacteroidetes to Firmicutes oscillates diurnally in WT 
mice (blue; p=0.01) but not in Bmal1 KO mice (red). (C, D) The relative abundances of 
Bacteroidetes and Firmicutes oscillate diurnally in WT mice (blue; p=0.007 and p=0.02 
respectively), but not in Bmal1 KO mice (red). NWT = 5, NBmal1 KO = 6. Mean ± S.E.M. 
shown.  
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JTK_CYCLE analysis revealed significant diurnal rhythmicity of the relative abundances 
of Bacteroidetes and Firmicutes in WT mice (p=0.008 and p=0.02 respectively) but none 
in Bmal1 KO mice (p=1 for both) (Figure 5.6 C, D). Accordingly, the ratio of 
Bacteroidetes to Firmicutes oscillated in WT mice, but not in Bmal1 KO mice (Figure 5.6 
B). The total bacterial load in both groups showed a similar fluctuating pattern, although 
those in Bmal1 KO mice were depressed relative to WT mice (Figure 5.6 A). Thus, 
although the bacterial load was unaltered, Bmal1 deletion abolished the diurnal 
oscillation of microbiota composition.  
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Figure 5.7 Bmal1 deletion abolishes the diurnal oscillation at genus level in mice. 
WT mice exhibited diurnal oscillations during the light-dark cycle in the abundances of 
S24-7 spp. (p=0.04), Lachnospiraceae spp. (p=9.9E-05), Oscillospira (p=0.0005), 
Bacteroides (p=0.006), and Clostridia spp. (p=0.001). None of these genera oscillated in 
Bmal1 KO mice. NWT = 5, NBmal1 KO = 6. Mean ± S.E.M. shown. 
 
In WT mice, the relative abundances of S24-7 spp., Lactobacillaceae spp., Baceroides, 
and Clostridia spp. showed significant diurnal oscillation. However, in Bmal1 KO mice, 
none of these oscillated (Figure 5.7). 
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5.3.3 Bmal1 deletion alters the microbiota composition 
The microbial community composition in Bmal1 KO mice and WT mice was different 
based on presence-absence analysis (Figure 5.8 A) (unweighted UniFrac distance, p=0.03) 
but only showed a trend toward differences in the abundance-weighted analysis 
(weighted UniFrac distance, p=0.19). The degree of difference between genotypes did not 
depend on the time of day when the samples were collected (unweighted UniFrac, 
p=0.97). Comparison of abundances at the phylum level revealed a significant decrease in 
the relative abundance of Proteobacteria as well as a significant increase of phylum TM7 
in Bmal1 KO mice compared to those in WT mice (Figure 5.8 B). The decrease in 
abundance of Proteobacteria was driven by the reduction of two genera, Helicobacter and 
Sutterella, whereas the increase of TM7 abundance was driven by the expansion of F16 
spp. (Figure 5.8 C, top and bottom). At the genus level, significant alterations in the 
relative abundances could be detected. Bmal1 deletion was associated with significant 
increases of Bacteroidales spp., Rikenellaceae spp., and Rikenella abundances (Figure 
5.8 C, top and middle), as well as significant decreases of S24-7 spp. abundance (Figure 
5.8 C, bottom) within the phylum Bacteroidetes. It was associated with significant 
increases of Clostridiales spp., Clostridiaceae spp., and Peptococcaceae spp. abundances 
(Figure 5.8 C, upper and middle), and significant decrease of Allobaculum abundance 
(Figure 5.8 C, bottom) within the phylum Firmicutes.  
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Figure 5.8 Bmal1 deletion alters bacterial relative abundances in fecal microbiota in 
mice. Fecal microbiota compositions from WT and Bmal1 KO mice were compared. (A) 
Fecal microbiota composition from individual WT mice (blue) and Bmal1 KO mice (red) 
were clustered separately according to Principal Coordinate Analysis of Unweighted 
UniFrac distances (let) and Weighted UniFrac distances (right). The percentages of 
variation explained by principal coordinates PC1 and PC2 are indicated on the x and y 
axes, respectively. (B) The relative abundance of Proteobacteria was decreased in Bmal1 
KO mice. The relative abundance of TM7 and unassigned species (Other) was increased 
in Bmal1 KO mice. (C) The relative abundances of bacterial genera were altered in 
Bmal1 KO mice. NWT = 5, NBmal1 KO = 6. Mean ± S.E.M. shown. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001 by Mann-Whitney test.   
5.3.4 Bmal1 deletion-induced changes in the microbiota are gender-dependent 
Principal Coordinate Analyses also revealed gender differences in the microbiota 
composition (Figure 5.9 A) (p=0.026 for unweighted UniFrac; p=0.007 for weighted 
UniFrac). The effect of Bmal1 deletion was the same for male and female mice. In male 
mice, Bmal1 deletion was associated with a significant decrease of Proteobacteria (Figure 
5.9 B) and increase of TM7 (Figure 5.9 C). In female Bmal1 KO mice, however, these 
phyla were not changed, but Cyanobacteria (Figure 5.9 D) and Tenericutes (Figure 5.9 E) 
increased. Bmal1 deletion-induced changes in female mice were not as substantial as 
those in male mice.  
 103 
 
 
 104 
 
Figure 5.9 Intestinal microbiota compositions of male and female mice respond 
differently to Bmal1 deletion. Fecal microbiota compositions from individual mice at all 
time points across the day were compared based on gender and genotype. (A) Fecal 
microbiota composition from individual male WT mice (green), female WT mice 
(orange), male Bmal1 KO mice (blue), and female Bmal1 KO mice (red) were clustered 
according to Principal Coordinates Analysis of Unweighted UniFrac distances (let) and 
Weighted UniFrac distances (right). Percentages of variation explained by principal 
coordinates PC1 and PC2 are indicated on the x and y axes. (B -E) Bacterial phyla 
abundances of WT (blue) and Bmal1 KO mice (red) in female and male mice were 
compared. Bmal1 deletion caused a decrease of Proteobacteria (B), and an increase of 
TM7 (C) in male mice. Female mice showed increased Cyanobacteria (D) and 
Tenericutes (E) after Bmal1 deletion. NWT = 5, NBmal1 KO = 6. Mean ± S.E.M. shown. * p 
< 0.05, ** p < 0.01, **** p < 0.0001 by Mann-Whitney test. 
  
The microbiota composition of male Bmal1 KO mice was more similar to female WT 
mice than to male WT mice (Mann-Whitney p<0.001 for unweighted and weighted 
UniFrac distance). In male Bmal1 KO mice, the relative abundances of Proteobacteria, 
TM7, and Tenericutes were significantly altered compared to male WT mice, resulting in 
comparable levels to those in female WT mice (Figure 5.9 B, C, E).  
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Figure 5.10 Differentially altered genera in female and male mice after Bmal1 
deletion. Bacterial genera abundances of WT (blue) and Bmal1 KO mice (red) in female 
and male mice were compared. In female mice, Bmal1 deletion was associated with 
increase of Bacteroidales spp., F16 spp., Clostridiaceae spp., Peptococcaceae spp., 
Ureaplasma, and decrease of Helicobacter, Lactobacillaceae spp.. In male mice, Bmal1 
deletion was associated with increase of Bacteroidales spp., Rikenellaceae spp., 
Bacteroidales spp., F16 spp., Clostridiales spp., Rikenella, Clostridiaceae spp., 
Ureaplasma, and decrease of Allobaculum, S24-7 spp., Helicobacter, Sutterella, 
Prevotella. NWT = 5, NBmal1 KO = 6. Mean ± S.E.M. shown. * p < 0.05, ** p < 0.01, **** 
p < 0.0001 by Mann-Whitney test.  
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Examination at the genus level revealed consistent results (Figure 5.10). In male mice, 
Bmal1 deletion caused significant increases of the relative abundances of Bacteroidales 
spp., Rikenellaceae spp., F16 spp., Clostridiales spp., Rikenella, and Clostridiaceae spp., 
as well as significant decreases of the relative abundances of Allobaculum, S24-7 spp., 
Sutterella, Prevotella, and Lactobacillaceae spp.. In female mice, Bmal1 deletion 
resulted in significant increases of Bacteroidales spp., Clostridiaceae spp., 
Peptococcaceae spp., Prevotella, and Ureaplasma, as well as significant decreases of 
Helicobacter and Lactobacillaceae spp..   
5.4 Discussion 
The intestinal microbiota composition is subject to changes induced by ageing, use of 
antibiotics, diet, and disease (Zoetendal, de Vos 2014, Zhao 2013, Wu, Bushman & 
Lewis 2013, Agans et al. 2011, De La Cochetiere et al. 2005). Here we provide evidence 
that the microbiota exhibit daily fluctuations, and begin to specify the factors that 
influence these oscillations. We report that both the fecal microbial load and its 
composition oscillate diurnally in mice during the light-dark cycle, consistent with two 
reports on circadian variations of the fecal microbiota composition (Thaiss et al. 2014, 
Zarrinpar et al. 2014), but this study is the first to show variation in the fecal bacterial 
load as well. We also find, unexpectedly, that this oscillation is more pronounced in 
female mice than in male mice. 
The relative abundance of both Bacteroidetes and Firmicutes oscillate diurnally (Figure 
5.3). Bacteroidetes peaked several hours after the beginning of the dark phase and 
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Firmicutes peaked around the beginning of the light phase. Cyclical fluctuations were 
also detected in abundances of lower level taxa, including Lachnospiraceae spp., 
Oscillospira, Ruminococcaceae spp., Clostridiales spp., Clostridia spp., and 
Anaeroplasma. In the recent metagenomic study, several strains in the intestinal 
microbiota have been shown to have a functional β-glucuronidase and represent a major 
de-glucuronidation pathway, including several major species from Firmicutes and 
Bacteroidetes (Gloux et al. 2011) such as Lachnospiraceae, Ruminococcaceae, and 
Clostridiaceae. Interestingly, the relative abundances of these bacterial lineages undergo 
circadian variations according to our and other’s studies. Together with our findings that 
the intestinal microbiota affects the pharmacokinetics and effect of indomethacin in mice 
partially via bacterial β-glucuronidase-mediated de-glucuronidation (Chapter 4), it is 
possible that the intestinal microbiota is partially contributing to the chronopharmacology 
of indomethacin in mice.  
To probe the determinants of circadian variation, we assessed microbiota oscillation in 
mice lacking Bmal1, the central component of the forward limb in host circadian clock. 
We found that the conventional Bmal1 deletion dampens the daily oscillation in both 
genders. We also report that conventional Bmal1 deletion shifts the microbiota 
configuration, and that the two genders are affected differently.  
Thaiss and colleagues found that the rhythmicity of microbiota composition is mostly lost 
after ablation of Per1 and Per2 genes, which are key components of the host molecular 
clock (Thaiss et al. 2014). A complication in the interpretation is that deletion of Per1 
and Per2 has pleiotropic effects extending beyond just circadian behavior, such as 
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involvement in cell growth and cell cycle regulation (Yu, Weaver 2011). Here we report 
that Bmal1 deletion, which leads to arhythmicity without pleiotropic effects, also 
abolishes the diurnal oscillation in fecal microbiota. Therefore, both activator (Bmal1) 
and repressor (Per1,2) genes in the core clock of the host are fundamental to the 
oscillation of fecal microbiota composition. This is strengthened by the finding that 
knockout of Bmal1 and the Per1,2 show similar phenotypes with microbiota rhythmicity. 
The mechanism underlying the effect needs further investigation.  
Therefore, it is essential to maintain a functional host circadian system, in order to 
maintain a healthy microbiota composition. Factors affecting the host circadian system, 
such as shift-work or chronic jet-lag, would have an influence on the microbiota circadian 
variation and composition, hence affecting the pharmacokinetics and efficacy of 
indomethacin.  
Rhythmicity of intestinal microbiota composition may also be affected by feeding 
behaviors. Mice are active in the dark phase (when lights are off from 7pm to 7am in our 
housing facility) and they consume the majority of their food during the first several 
hours of the dark phase (Paschos et al. 2012). Fasting is associated with expansion of 
Bacteroidetes and ingestion of food with an increase of Firmicutes (Costello et al. 2010, 
Crawford et al. 2009). During the day, when the mice are resting and consuming less 
food, Bacteroidetes are predominant, reaching the highest abundance towards the end of 
the light phase. When the lights go off, mice start eating. This is associated with the 
expansion of Firmicutes and proportional reduction of Bacteroidetes. By restricting the 
feeding of Per1/2 KO mice to dark phase or light phase, the diurnal microbial oscillation 
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was restored (Thaiss et al. 2014). Partial restoration of microbial oscillation is evident by 
consolidating high-fat diet feeding to dark phase (Zarrinpar et al. 2014). However, since 
circadian rhythms of host behavior and physiology can be entrained by daily cycles of 
restricted feeding (Stephan 1984, Boulos, Rosenwasser & Terman 1980), it is possible 
that consolidation of feeding to the dark phase only partially restored the circadian 
rhythm of the host. Hence, it remains to be determined whether the restoration of 
microbial oscillation is due to a direct influence of feeding, due to restoration of the host 
circadian clock, or due to the combination of the two.   
The influence of feeding on microbiota structure may result from varying nutrient 
availability. Glycans and polysaccharides from the diet and from the host mucus are 
essential carbon sources for growth of intestinal bacteria (Koropatkin, Cameron & 
Martens 2012). Unlike the host-derived glycans which are constantly available, dietary 
glycans fluctuate in both composition and abundance due to feeding. As an adaption to 
this, several bacterial strains in the Bacteroidetes phylum evolved to utilize host mucosal 
glycans when dietary glycans are in short supply (Martens, Chiang & Gordon 2008, 
Sonnenburg et al. 2005). Thus, bacterial strains that use only dietary glycans become 
proportionally reduced when the host is fasting, whereas bacteria that can use host-
derived glycans, such as Bacteroidetes, increase. This may explain the expansion of 
Bacteroidetes during fasting and the increase of Firmicutes after food intake.   
We found that Bmal1 both mediates circadian rhythms and influences microbiota 
composition. Bmal1 deletion shifted the microbiota configuration toward a phenotype 
that may be pro-inflammatory. For example, an increase of TM7 has been shown to be 
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associated with the development of periodontal disease (Brinig et al. 2003) as well as the 
inflammatory gastrointestinal disorders (Kuehbacher et al. 2008), probably by changing 
the growth environment for competing bacteria. Subphylum changes also indicate the 
likelihood of mild inflammation. An increase in Rikenellaceae abundance has been found 
as a result of high-fat diet feeding (Kim et al. 2012) and during the pathological 
progression of inflammatory bowel disease (Alkadhi et al. 2014). An increase of 
Clostridiaceae had been found in patients following ileal pouch-anal anastomosis (Scarpa 
et al. 2011, Tannock et al. 2012), in patients with ulcerative colitis and Crohn’s disease 
(Zhang et al. 2013), and also in mice during the progression of lupus (Zhang et al. 2014b). 
A decrease of Allobaculum has also been found in mice fed a high-fat diet (Qiao et al. 
2014). However, Proteobacteria, associated with host inflammation (Mukhopadhya et al. 
2012), were decreased after Bmal1 ablation. Our findings do not presently identify the 
mechanism through which Bmal1 affects the configuration of the microbiota and it is also 
unknown whether deletion of the period genes influenced taxonomic composition (Thaiss 
et al. 2014).  
Our study highlights the effect of gender on the composition of the fecal microbiota. 
Although microbiota in both males and females exhibited diurnal oscillations, females 
showed more significant rhythmicity than males (Figure 5.3). Oscillation in both genders 
depended on a functional host circadian clock, since Bmal1 deletion abolished the 
rhythmicity irrespective of gender. Thaiss and colleagues also reported near-complete 
loss of diurnal oscillation of microbiota in Per1/2 deficient mice, irrespective of gender 
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(Thaiss et al. 2014). Therefore, although secondary to the effect of the circadian clock, 
host gender also shapes the rhythmicity of composition.   
We also found that gender conditioned the impact of Bmal1 deletion on microbiota 
composition (Figure 5.9, Figure 5.10), indicating an interaction between gender and 
genotype. There are some previous suggestions of the relevance of gender to the 
microbiota. For example, male and female microbiota diverge after puberty in mice and 
this reflects the gender bias in expression of autoimmune diseases, such as type 1 
diabetes (Markle et al. 2013, Yurkovetskiy et al. 2013). Sexual dimorphism in the 
microbiota has also been reported in macaques (McKenna et al. 2008). Although the 
mechanism remains unclear, a bidirectional interaction between microbiota and host 
hormone levels seems likely, since the divergence between male and female microbiota 
can be reversed by male castration (Markle et al. 2013). Moreover, differential effects of 
dietary manipulation are conditioned by gender in fish, mice and potentially humans 
(Bolnick et al. 2014).  
In summary, the composition of the fecal microbiota exhibits diurnal oscillation that 
requires a functional host circadian clock, as indicated by comparison of the Bmal1 
deletion. Bmal1 also had a role in specifying the composition of the microbiota, and this 
was affected by host gender. Our findings thus specify pathways of host regulation of the 
composition of fecal microbiota and motivate exploration of the host circadian clock and 
microbial circadian rhythmicity. Our study and previous work (Thaiss et al. 2014, 
Zarrinpar et al. 2014) suggest the need to include consideration of animal gender and 
genotype, feeding pattern, and timing of sample collection in studies of the microbiota. 
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Moreover, our study provides initial evidence documenting the involvement of intestinal 
microbiota in the chronopharmacology of indomethacin.   
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Chapter 6 Conclusions and Future Directions 
6.1 Conclusions 
This thesis supports the following conclusions: 
1. In untreated mice, the microbial load and composition vary considerably from the 
proximal to the distal end of the intestine, as well as between the luminal content 
and mucosal tissue. The microbiota composition in the small intestine has greater 
inter-individual variation in both luminal content and mucosal tissue. 
2. A single oral dose of indomethacin, which has the potential to induce small 
intestinal damage, altered microbial diversity in the distal intestine and caused 
compositional changes along the intestine without affecting the microbial biomass. 
3. Indomethacin induces changes in microbial diversity and composition in feces, 
shifting the microbial community towards a pro-inflammatory phenotype.  
4. The half-life and volume of distribution of indomethacin was significantly 
reduced in mice treated with antibiotics. This is partially due to impaired de-
glucuronidation mediated by bacterial β-glucuronidase.  
5. Both the fecal microbial load and its composition oscillate diurnally in mice 
during the light-dark cycle. This oscillation is regulated by host circadian clock at 
an early stage of life.  
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6.2 Future directions 
The research in this thesis prompts new questions and opens the door for future 
investigations.  
We established the association of indomethacin administration with altered intestinal 
microbiota composition. The expansion of Peptococcaceae and Erysipelotrichaceae has 
been previously been associated with inflammatory disease (Harris et al. 2014, Zhang et 
al. 2009, Zhu et al. 2014, Kaakoush et al. 2015). Similarly, the increased ratio of 
Firmicutes to Bacteroidetes in the fecal microbial community has been associated with 
obesity (Ley et al. 2005, Turnbaugh et al. 2006). However, whether the alterations in 
intestinal microbiota composition play a role in the pathogenesis of indomethacin-
induced intestinal damage and whether this effect is through direct interaction or indirect 
interference needs further study. Since COX-2 specific inhibitors showed a better 
gastrointestinal safety profile than tNSAID comparators (Bombardier et al. 2000, 
Silverstein et al. 2000), this question can be partially addressed by comparing the 
influences of NSAIDs that favor COX-1 inhibition, such as naproxen or other compounds, 
versus that of NSAIDs that are specific for COX-2 inhibition, such as celecoxib 
(FitzGerald, Patrono 2001). 
In addition, the mechanism via which indomethacin causes these changes are not 
revealed in this study. Further experiments are needed to assess the following: i) whether 
or not indomethacin is directly affecting the growth of intestinal bacteria by providing a 
nutritional source that can be uniquely utilized by specific species; ii) whether or not 
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COX-1 and COX-2 inhibition is involved in indomethacin-induced compositional 
changes in intestinal microbiota, and if so, what are the downstream mediators; iii) 
whether COX-1 or COX-2 inhibition is the major driver of indomethacin-induced 
changes. The first question can be addressed by in vitro screening of bacteria whose 
growth can be affected by the presence of indomethacin in the culture media. The second 
question can be addressed by investigating the intestinal microbiota composition in 
genetically modified mouse models, such as those lacking COX-1 or COX-2. Further, 
tissue-specific knockout mice, can be used to elucidate the influence of COX-1 and 
COX-2 enzymes. The third question can also be addressed by using pharmacological 
probes.  
This thesis research revealed the diurnal oscillation of several bacterial strains that has 
been predicted to have functional β-glucuronidases activity. Given the 
chronopharmacology of indomethacin, it is important to study whether the circadian 
effect is attributable to the diurnal oscillation of intestinal microbiota. This can be 
addressed by: i) studying the pharmacokinetics of indomethacin in germ-free mice or 
antibiotic-treated mice receiving indomethacin in the mornings versus in the evenings; ii) 
studying the pharmacokinetics of indomethacin in gnotobiotic mice co-colonized with 
bacterial strains with predicted β-glucuronidases activity.  
This thesis research investigated the acute effect of indomethacin administration. 
However, long-term use of NSAIDs by patients is quite common. Hence, it is worthwhile 
to investigate the influence of indomethacin on intestinal microbiota after chronic 
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administration. Further, naproxen and celecoxib can also be studied to differentiate COX-
1 inhibition versus COX-2 inhibition.  
Bacteria-mediated de-glucuronidation has been identified as one potential mechanism 
through which intestinal microbiota affect the pharmacokinetics and efficacy of 
indomethacin. To further confirm the involvement of intestinal bacteria, the following 
approach can be used: i) compare the pharmacokinetics of indomethacin in germ-free 
mice versus conventional mice; ii) compare the pharmacokinetics of indomethacin in 
mice treated with or without bacteria-specific inhibitors for β-glucuronidases developed 
previously (Roberts et al. 2013, Saitta et al. 2014).  
Co-administration of antibiotics with NSAIDs is common in orthopedic patients. 
Therefore, it is important to study whether the pharmacokinetic and pharmacodynamics 
changes reported in this thesis research would be generalized to human populations and 
whether this influence would limit the efficacy of NSAIDs in these patients.  
The importance of intestinal microbiota is more and more appreciated in the past several 
years. This thesis research is the first to document the bidirectional interactions between 
host-targeting medication and intestinal microbiota, phenomena that are closely relevant 
to human health and disease.  
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